Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity

*American Diabetes Association Professional Practice Committee for Obesity**

https://doi.org/10.2337/doci25-0008

Obesity medications may be part of a comprehensive care plan for adults with obesity. The Obesity Association, a division of the American Diabetes Association (ADA), developed comprehensive, evidence-based guidelines on the pharmacologic treatment of obesity in adults. When used in conjunction with lifestyle modifications, obesity medications have demonstrated efficacy in inducing and sustaining weight reduction while concurrently improving clinical outcomes of obesity and obesity-related diseases and complications. Health care professionals should engage people with obesity in a person-centered, shared decision-making approach when selecting an obesity medication to optimize health outcomes while emphasizing individual needs and preferences. The ADA's Obesity Association encourages health care professionals to adopt these guidelines for treatment of obesity in adults.

Obesity medications are an essential component of a comprehensive approach to obesity management, offering significant benefits beyond lifestyle interventions alone for many people. Research indicates that pharmacotherapy can lead to greater weight reduction and improved weight maintenance than placebo in adults with obesity (1). Of note, randomized controlled trials (RCTs) of obesity medications include lifestyle intervention in both placebo and study drug arms, which most typically comprises a 500-calorie deficit meal plan and behavioral intervention that usually produces 2.6% weight reduction in the placebo group (2), and the placebo group receives a placebo pill or injection, as appropriate. In meta-analyses of RCTs, people treated with obesity medications experienced substantial weight reduction compared with placebo (2,3). Participants treated with obesity medications also had improvements in cardiometabolic markers, such as glycemia and lipid profiles (2,3), and some obesity medications demonstrated improvements in cardiovascular outcomes and other obesity-related diseases (4–7). When used appropriately, obesity medications offer a favorable risk-benefit profile in many cases, making them a viable option for many people with obesity.

Multiple weight-regulating hormones change in response to weight reduction, creating a physiologic environment conducive to the body returning to its higher prior weight (8,9). Weight reduction also negatively affects energy expenditure and basal metabolic rate, which makes weight-loss maintenance challenging for individuals with obesity (10,11). However, obesity medications enhance the ability to reduce weight and maintain weight reduction over extended periods (12), and many target the dysregulated neurohormonal systems that cause weight gain and prevent sustained weight reduction (13). Over the past few decades, substantial progress has been made regarding the efficacy and safety of obesity medications (14), and multiple obesity medications are now available that result in sustained weight reduction and improvements in multiple obesity-related diseases and complications. By discussing and considering obesity medications for adults with obesity, health care professionals can offer an effective treatment strategy that addresses overall health where treatment goals extend beyond weight reduction to include improving obesity-related diseases and complications, physical function, and well-being.

Corresponding author: Elizabeth J. Pekas, epekas@diabetes.org

*A complete list of members of the American Diabetes Association Professional Practice Committee for Obesity can be found in the appendix at the end of the article.

This section has been reviewed and approved by the ADA Board of Directors.

This section has received endorsement from The Obesity Society, Obesity Action Coalition, Obesity Medical Association, and American Board of Obesity Medicine Foundation.

This article is being simultaneously published in *Diabetes, Obesity, and Cardiometabolic CARE* and *BMJ Open Diabetes Research & Care*.

The methodology for the "Standards of Care in Overweight and Obesity" has been described previously (15). These guidelines are developed by the American Diabetes Association (ADA) Professional Practice Committee for Obesity, an interprofessional team of experts. Subcommittees conduct systematic literature reviews to inform updates, guided by a methodologist and librarian. Recommendations are graded based on evidence quality (A, B, C, or expert opinion E) with the strongest evidence derived from large, well-designed RCTs. While evidence forms the basis, recommendations emphasize person-centered care. Recommendations are deliberated by Professional Practice Committee voting members, with an 80% consensus required for approval. External peer reviews and adherence to established guideline development principles ensure credibility and rigor in this approach. Of note, this section uses the term obesity medications; the terms obesity management medications and anti-obesity medications may also be used in the literature to refer to these medications.

This section includes only medications approved by the U.S. Food and Drug Administration (FDA) for the treatment of obesity among individuals with obesity or individuals with overweight and the presence of at least one obesity-related disease or complication. It does not include medications without an approved indication for obesity (e.g., metformin), medications FDA-approved to treat rare genetic conditions associated with obesity (e.g., setmelanotide for Bardet-Biedl syndrome), or FDA-approved devices to treat obesity (e.g., oral cellulose–citric acid hydrogel).

Discussing Obesity Medications

Recommendations

2.1 Select obesity medications using a person-centered approach that incorporates shared decision-making and is grounded in the best available evidence **B**.

2.2 Prioritize obesity medications most likely to achieve and maintain intended treatment goals while considering cost, access, tolerability, risk for adverse effects, and individual preferences **A**.

2.3 Nutrition, physical activity, and behavioral therapy should be used in combination with obesity medications to achieve health goals **A**.

2.4 Whenever clinically appropriate, minimize use of weight-promoting medications used to treat other conditions, particularly among adults with obesity **A**.

Shared decision-making fosters a collaborative partnership between health care professionals and individuals with obesity, integrating person-specific factors (e.g., goals, values, and preferences) into the decision-making process. In general, shared decision-making reduces decisional conflict, improves individuals' knowledge of diseases and treatment options, and increases satisfaction with treatment decisions (16,17). For example, a meta-analysis (18 RCTs) showed that shared decision-making for cardiovascular risk management improved hemoglobin A1c (A1C) (17). Future work is needed to design shared decision-making tools specific to obesity medications.

As obesity medications induce clinically meaningful weight reduction relative to placebo (2,18), the choice of therapy should prioritize medications most likely to improve obesity-related diseases and complications and to achieve and maintain weight reduction goals. Therefore, this section outlines an approach focused on reducing risk of and burden from obesity-related diseases rather than solely focusing on weight reduction goals. Table 2.1 contains a summary of treatment and weight-reduction outcomes as well as adverse effects reported in RCTs of obesity medications. The risk of medication-related adverse effects should be evaluated for each individual, as this risk may vary depending on their medical history and concomitant medications. In a network meta-analysis (132 RCTs), adverse events leading to drug discontinuation were significantly higher for all obesity medications compared with placebo (2). Health care professionals should present the potential benefits, risks, and expected outcomes of obesity medications. Medication selection should be guided by person-centered factors, including evidence, treatment burden, costs, and individuals' therapeutic goals and preferences.

Behavioral Lifestyle Therapy With Obesity Medications

Nutrition, physical activity, and behavioral therapy must be components of all comprehensive obesity treatment plans, including those with obesity medications. The efficacy of obesity treatment interventions that include nutrition and physical activity have been documented in meta-analyses (1,19,20), and the addition of obesity medications to lifestyle interventions improves weight reduction and weight-loss maintenance (1,19,21).

Greater weight reduction may be achieved when a lifestyle behavioral modification program is administered with an obesity medication among individuals with obesity (22–25). For example, in a 1-year RCT, participants in a naltrexone-bupropion plus intensive behavioral program group lost 9.3% of baseline weight compared with 5.1% in the placebo plus intensive behavioral program group (22). The degree of weight reduction achieved is related to program intensity (20), and engagement in behavioral components is also associated with greater weight reduction (26). Some obesity medications are associated with increased fullness as well as decreased hunger, food preoccupation, dietary disinhibition, and binge eating compared with placebo (27,28), which may aid individuals in achieving and sustaining the lifestyle treatment plan.

Weight-Promoting Medications

Before prescribing an obesity medication, health care professionals should carefully review individuals' concomitant

TABLE 2.1 Summary of features of FDA-approved obesity medications influencing medication selection

Medication	Contraindications	Placebo-subtracted weight reduction in meta-analysis*	Effects on obesity-related diseases and complications†	Estimated costs‡	Common adverse effects	Strategies to manage adverse effects§	Clinical suggestions and monitoring
Orlistat	• Malabsorption • Cholestasis	3.1%	Demonstrated benefit • BP Potential benefit • T2D	Moderate	• Oily fecal spotting • Oily stools • Flatulence • Fecal urgency • Increased defecation	• Follow low-calorie meal plan with <30% of calories from fat to reduce GI effects • Avoid high-fat meal plan, as it increases adverse effects (e.g., ketogenic, low-carbohydrate)	• Advise that GI adverse effects typically subside within 4 weeks • Use MVI containing fat-soluble vitamins at bedtime to avoid deficiencies
Phentermine	• CVD • Uncontrolled HTN • Glaucoma • Hyperthyroidism • SUD • Agitated states	3.6%	Unknown	Low	• Dry mouth • Insomnia • Headache • Irritability • Constipation	• Adequate water and dietary fiber intake to manage dry mouth and constipation • Avoid taking medication in the evening to reduce insomnia	Monitor • Heart rate and BP for increases with initiation and dose escalation
Phentermine-topiramate	• CVD • Uncontrolled HTN • Glaucoma • Hyperthyroidism	8.8%	Potential benefit • T2D • BP • OSA	Moderate	• Paresthesia • Dry mouth • Headache • Constipation • Insomnia • Altered taste • Cognitive impairment	• Adequate water intake to manage dry mouth, constipation, and reduce risk of kidney stones • Adequate fiber intake to manage constipation • Take medication in the morning to reduce insomnia • Paresthesia or cognitive changes, if bothersome, may improve with reduced dose	• Advise people of childbearing potential of teratogenicity and counsel on need for effective contraception Monitor • Heart rate and BP for increases with initiation and dose escalation • Mood changes • Electrolytes for changes in renal function
Naltrexone-bupropion	• Uncontrolled HTN • Seizure disorders • Glaucoma • Anorexia or bulimia • SUD • Chronic opioid use	4.8%	Potential benefit • T2D No benefit • BP	Moderate	• Nausea • Constipation • Vomiting • Headache • Dizziness • Dry mouth	• Reduce portion size to manage nausea • Adequate water and dietary fiber intake to manage dry mouth and constipation • Administer evening dose at least 3 h before bedtime to reduce insomnia • Avoid high-fat meal plan, as it increases adverse effects (e.g., ketogenic, low-carbohydrate)	Monitor • BP for increases with initiation and dose escalation • Mood changes
Liraglutide	• Severe GI disease • Personal or family history of medullary thyroid carcinoma or MEN type 2	4.5%	Demonstrated benefit • T2D‖ Potential benefit • BP • ASCVD • MASH • OSA • OA	High	• Nausea • Vomiting • Diarrhea • Constipation • Headache • Dyspepsia • Increased heart rate	• Reduce portion size to manage nausea • Adequate water and dietary fiber intake to manage constipation • Last meal at least 2 h before bedtime to reduce dyspepsia	• Rotate injection site location to reduce pain • Refrigerate medication • Advise people on concurrent insulin or sulfonylureas of hypoglycemia risk Monitor • Heart rate • Mood changes

Continued on p. 4 »

« Continued from p. 3

TABLE 2.1 Summary of features of FDA-approved obesity medications influencing medication selection (Continued)

Medication	Contraindications	Placebo-subtracted weight reduction in meta-analysis*	Effects on obesity-related diseases and complications†	Estimated costs‡	Common adverse effects	Strategies to manage adverse effects§	Clinical suggestions and monitoring
Semaglutide	• Severe GI disease • Personal or family history of medullary thyroid carcinoma or MEN type 2	11.9%	Demonstrated benefit • T2D‖ • BP • ASCVD‖ • HFpEF • MASH‖ • OA	High	• Nausea • Vomiting • Diarrhea • Constipation • Dyspepsia • Headache • Fatigue • Increased heart rate	• Reduce portion size and dietary fat to manage nausea • Adequate water and dietary fiber intake to manage constipation • Last meal at least 2 h before bedtime to reduce dyspepsia	• Rotate injection site location to reduce pain • Refrigerate medication • Consider MVI daily to avoid micronutrient deficiencies • Advise people with T2D of diabetic retinopathy risk • Advise people on concurrent insulin or sulfonylureas of hypoglycemia risk Monitor • Heart rate • Mood changes • Symptoms of cholelithiasis • Electrolytes for changes in renal function
Tirzepatide	• Severe GI disease • Personal or family history of medullary thyroid carcinoma or MEN type 2	16.2%	Demonstrated benefit • T2D‖ • BP • OSA‖ Potential benefit • ASCVD • HFpEF • MASH • OA	High	• Nausea • Vomiting • Diarrhea • Constipation • Dyspepsia	• Reduce portion size and dietary fat to manage nausea • Adequate water and dietary fiber intake to manage constipation • Last meal at least 2 h before bedtime to reduce dyspepsia	• Rotate injection site location to reduce pain • Refrigerate medication • Consider MVI daily to avoid micronutrient deficiencies • Advise people on concurrent insulin or sulfonylureas of hypoglycemia risk Monitor • Mood changes • Symptoms of cholelithiasis • Electrolytes for changes in renal function

ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; CVD, cardiovascular disease; FDA, U.S. Food and Drug Administration; GI, gastrointestinal; HFpEF, heart failure with preserved ejection fraction; HTN, hypertension; MASH, metabolic dysfunction–associated steatohepatitis; MEN, multiple endocrine neoplasia syndrome; MVI, multiple vitamin and mineral; OA, osteoarthritis; OSA, obstructive sleep apnea; SUD, substance use disorder; T2D, type 2 diabetes. *Values reflect placebo-subtracted mean percent weight loss estimated in meta-analyses to represent the weight reducing effect of the obesity medication beyond that achieved with lifestyle change alone (51,52). These meta-analyses include individuals with obesity both with and without obesity-related diseases and complications. Lifestyle counseling achieved 2.6% weight reduction in meta-analyses (2). Given that obesity medications should be used in combination with lifestyle changes, the total anticipated weight reduction effect would be the combined effect of the obesity medication plus lifestyle (e.g., 3.1% for orlistat plus 2.6% for lifestyle counseling would total 5.7% anticipated weight loss). Intensive behavioral therapy typically results in greater magnitude of weight reduction relative to lower intensity lifestyle counseling; therefore, the combination of obesity medication with intensive behavioral therapy may result in greater total anticipated weight reduction effect. Individual responses to obesity treatment may vary. †Obesity-related diseases and complications considered include T2D, BP, MACE, HFpEF, MASH, OSA, and OA. Obesity medications with A-level evidence of beneficial outcomes identified as "demonstrated benefit" for outcomes related to the specified condition, whereas those with B- or C-level evidence of beneficial outcomes identified as "potential benefit." "No benefit" indicates that there is evidence of no beneficial effects on the outcome. If an outcome for one of the obesity-related diseases or complications is not listed, then the effect on this condition is unknown (i.e., there is no evidence evaluating the obesity medication on the outcome). ‡Individuals may experience cost barriers in accessing obesity medications due to a lack of insurance coverage, high copays, or other high out-of-pocket costs. Information presented in this column represents estimated out-of-pocket costs without insurance and using discount programs available from the manufacturer. "Low" is defined if estimated costs are less than $100/month, "moderate" if $100-$200/month, or "high" if greater than $200/month. Actual costs for the individual obtaining the medication may differ from these estimates. §Most adverse effects will improve with reduction in obesity medication dose, and a slow dose escalation may reduce the likelihood of adverse effects and improve tolerability. Not all individuals need the maximum approved dose of the medication. ‖These are medications currently FDA-approved for the treatment of the identified obesity-related disease or complication.

medications, as studies have found that medications that promote weight gain are commonly used, including among individuals with obesity (29–31). Health care professionals should be aware of weight-promoting medications (Table 2.2) (32). As the number of prescribed weight-promoting medications increases, individuals' BMI and waist circumference are more likely to have greater increases over time (33). In addition, studies have found that participants using weight-promoting medications have reduced weight-loss efficacy with lifestyle interventions to treat obesity (34,35).

Whenever possible and clinically appropriate, avoid initiating a prescription for weight-promoting medications among individuals with obesity and instead select a non-weight-promoting alternative. For example, ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, and diuretics should be prioritized to treat hypertension rather than some β-blockers, as these options are weight-neutral rather than weight-promoting. When diabetes medications are needed for glycemic management, medications most likely to cause weight gain should be discouraged in favor of alternatives that are non-weight-promoting (Table 2.2). However, health care professionals should not refrain from prescribing weight-promoting medications when needed to achieve treatment goals for that condition (e.g., blood pressure in hypertension).

For individuals with obesity who may already be using weight-promoting medications, health care professionals should determine whether a dose reduction or non-weight-promoting alternative may be clinically appropriate. If so, individuals should be engaged in determining whether their medication plan should be modified, accounting for the benefits and risks of all treatment options. Health care professionals should be aware that cessation of weight-promoting medications does not necessarily result in weight reduction. For individuals who must remain on weight-promoting medications, obesity medications may be beneficial in achieving treatment and weight goals.

Setting Treatment Goals With Obesity Medications

Recommendations

2.5a Treatment goals should be incremental and individualized, based on the severity of obesity, obesity-related diseases and complications, and individuals' needs, life circumstances, and preferences **E**.

2.5b Aim for a sustained reduction in baseline body weight of ≥5% for adults treated with obesity medications, which may achieve some clinically meaningful health benefits **A**. Aim for a sustained weight reduction of ≥10% to manage many obesity-related diseases or complications **A**; in some cases, a ≥15% weight reduction may be indicated to achieve greater therapeutic benefit **B**.

Obesity is a heterogeneous disease with varying effects on health, necessitating individualized treatment plans. Sociocultural factors and personal motivation also play a critical role in treatment goals. Culturally tailored interventions that respect individual preferences and lived experiences, rather than those that impose rigid weight-loss goals, are needed. Health care professionals should evaluate each individual for obesity-related diseases and complications as well as physical symptoms, psychological symptoms, functional limitations, and impact on well-being due to excess adiposity (36,37). Such a holistic assessment will highlight the need for tailored treatment goals, as health risks and weight-reduction benefits vary by the severity of obesity and its related diseases and complications. Health care professionals should be aware that the typical time course to achieve treatment goals varies between individuals; therefore, reevaluation every 3 months may be useful to monitor progress.

Achieving a ≥5% reduction in baseline body weight for adults treated with obesity medications is associated with health benefits (18,38–42). Research demonstrates that a 5% weight reduction improves cardiometabolic risk factors (2,43,44). For example, the CONQUER RCT demonstrated that over 60% of participants treated with phentermine-topiramate achieved ≥5% weight reduction as compared with 21% with placebo, and weight reduction was accompanied by improvements in metabolic risk factors (40). In the SURMOUNT-1 RCT, over 85% of participants who received tirzepatide achieved a ≥5% reduction goal compared with 35% with placebo; notable improvements in cardiometabolic measures were also observed (18).

For individuals with obesity-related diseases and complications, achieving ≥10% reduction in baseline body weight has consistently demonstrated improvements in these conditions. In general, 10–15% weight reduction results in significantly greater improvements in glycemia, blood pressure, and lipids compared with 5–10% loss (45). In most cases, the magnitude of weight reduction is directly proportional to risk factor improvements; therefore, sustained weight reduction of ≥10% is often required for optimal cardiometabolic benefits. Obesity-related diseases and conditions that benefit from this weight-loss magnitude include metabolic dysfunction–associated steatohepatitis with moderate-to-severe fibrosis (7,46), heart failure with preserved ejection fraction (47,48), and knee osteoarthritis (49).

Emerging data suggest that ≥15% weight reduction may be needed to achieve clinical benefits in some cases (45), particularly for individuals with moderate-to-severe obesity-related conditions. In the SURMOUNT-OSA trial, participants with obesity and moderate-to-severe obstructive sleep apnea who received tirzepatide achieved mean weight reduction exceeding 15% and experienced significant reductions in the apnea-hypopnea index (AHI), hypoxic burden, and systolic blood pressure compared with placebo (6). A meta-analysis found a dose-response relationship between AHI and weight

TABLE 2.2 Weight-promoting medications and alternatives

Condition	Weight-promoting medications	Non-weight-promoting alternatives
Hypertension	α-Blockers Metoprolol Propranolol Atenolol	ACE inhibitors ARBs Carvedilol Nebivolol Thiazide and thiazide-like diuretics
Diabetes	Insulin Sulfonylureas Thiazolidinediones	α-Glucosidase inhibitors Metformin* GLP-1 receptor agonists* Dual GIP and GLP-1 receptor agonist* SGLT2 inhibitors* Vidagliptin* Sitagliptin* Other DPP-4 inhibitors Pramlintide*
Contraception	Depo-medroxyprogesterone acetate Progestins	Copper IUDs Barrier contraceptive methods
Allergies	Diphenhydramine Cetirizine Hydroxyzine Fexofenadine Meclizine Cyproheptadine	Loratadine
Depression	Nortriptyline Doxepin Amitriptyline Imipramine Phenelzine Paroxetine Escitalopram Citalopram Fluoxetine† Sertraline† Mirtazapine	Bupropion*
Psychosis	Clozapine Olanzapine Risperidone Quetiapine Perphenazine Aripiprazole	Ziprasidone
Mood instability	Lithium	Ziprasidone Lamotrigine
Epilepsy	Gabapentin Pregabalin Valproic acid Vigabatrin Carbamazepine	Lamotrigine Levetiracetam Phenytoin Topiramate* Zonisamide* Felbamate*
Inflammation	Glucocorticoids	NSAIDs
Other	Megestrol acetate	

This table was adapted with permission from *Clinical Management of Obesity*, 3rd edition (260). ARB, angiotensin receptor blocker; DPP-4, dipeptidyl peptidase 4; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide 1; IUD, intrauterine device; NSAID, nonsteroidal anti-inflammatory drug; SGLT2, sodium–glucose cotransporter 2. *Alternative medication is associated with weight reduction; otherwise, alternative medications are considered weight neutral. †Short-term use of less than 12 months is typically weight neutral, while long-term use is associated with weight gain.

change (6), where a 20% weight reduction lowers AHI by 57% and a 30% weight reduction lowers AHI by nearly 70%.

Ultimately, individualized goals should be determined based on a comprehensive assessment, including disease severity, risk-benefit considerations, motivation, and personal circumstances. While weight-reduction goals of ≥15% may be beneficial for some individuals with moderate-to-severe obesity-related diseases, others may experience meaningful health improvements with less weight reduction. Personalized treatment strategies may lead to long-term success and sustainability.

Selecting Obesity Medications

Recommendations

2.6a In adults with obesity who do not have obesity-related diseases or complications, consider obesity medications as part of the treatment plan to promote weight reduction, prevent further weight gain, and reduce the risk of developing obesity-related diseases and complications **A**, **C** (Fig. 2.1).

2.6b Obesity medications should be offered as part of initial treatment for obesity to adults with or at high risk of obesity-related diseases or complications **A**.

2.7 In adults with overweight or obesity and prediabetes, the treatment plan should prioritize obesity medications with demonstrated evidence for preventing progression to type 2 diabetes **A**, **B** (Fig. 2.2).

2.8 In adults with overweight or obesity and type 2 diabetes, the preferred obesity medication should be a glucagon-like peptide 1 receptor agonist (GLP-1RA) or a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist (dual GIP/GLP-1RA) given their weight reduction and glucose-lowering efficacy **A**. If a preferred obesity medication is unable to be used, other obesity medications with demonstrated glucose-lowering efficacy may be considered within the context of their risks and adverse effects **B** (Fig. 2.2).

2.9 In adults with overweight or obesity and essential hypertension, the treatment plan should prioritize obesity medications with demonstrated blood pressure reduction benefit **A**, **B** (Fig. 2.2).

2.10 In adults with overweight or obesity and established atherosclerotic cardiovascular disease, the treatment plan should include a GLP-1RA with demonstrated benefits **A**, **B** or a dual GIP/GLP-1RA with potential benefits in reducing cardiovascular events **B** (Fig. 2.2).

2.11 In adults with overweight or obesity and heart failure with preserved ejection fraction, the treatment plan should include a GLP-1RA or dual GIP/GLP-1RA with demonstrated improvements in heart failure-related symptoms **A** or reduction in heart failure events **A**, **B** (Fig. 2.2).

2.12 In adults with overweight or obesity and metabolic dysfunction–associated steatohepatitis (MASH) with moderate or advanced fibrosis, the treatment plan should include a GLP-1RA or a dual GIP/GLP-1RA with demonstrated or potential benefits on MASH **A**, **B**, **C** (Fig. 2.2).

2.13 In adults with overweight or obesity and moderate-to-severe obstructive sleep apnea, the treatment plan should prioritize obesity medications with demonstrated improvements in sleep apnea **A**, **B**, **C** (Fig. 2.2).

2.14 In adults with overweight or obesity and moderate osteoarthritis, the treatment plan should prioritize a GLP-1RA or dual GIP/GLP-1RA with potential improvements in osteoarthritis symptoms **B**, **C** (Fig. 2.2).

The FDA has approved several obesity medications as adjuncts to a reduced-calorie meal plan and increased physical activity in individuals with obesity or individuals with overweight and the presence of at least one obesity-related disease or complication. Historically, label-defined eligibility criteria were BMI $\geq$30 kg/m^2 or $\geq$27 kg/m^2 with one or more obesity-related disease or complication; however, these thresholds are no longer included in the labels of several obesity medications (i.e., phentermine-topiramate, liraglutide, semaglutide, and tirzepatide). Table 2.3 describes the mechanisms of action and dosing for all FDA-approved obesity medications. Most obesity medications are approved for long-term treatment; the exception is monotherapy with phentermine or other adrenergic agents (e.g., diethylpropion) that were approved for short-term use. Obesity medications are invaluable components of initial treatment in adults who already have or who are at high risk of developing obesity-related diseases or complications, as they can significantly mitigate the progression of these conditions (4,6,47,48). If individuals with obesity-related diseases or complications initially decline obesity medication, it may be appropriate to reevaluate their interest in this treatment option at follow-up.

All FDA-approved obesity medications have demonstrated weight-reduction efficacy in clinical trials (18,38–42,50). In a network meta-analysis, in comparison with placebo at study end point, orlistat was associated with 3.1% greater weight reduction (22 RCTs), phentermine-topiramate was associated with 8.8% greater weight reduction (5 RCTs), naltrexone-bupropion was associated with 4.8% greater weight reduction (2 RCTs), liraglutide was associated with 4.5% greater weight reduction (10 RCTs), semaglutide was associated with 11.9% greater weight reduction (13 RCTs), and tirzepatide was associated with 16.2% greater weight reduction (6 RCTs) (51). Of note, these meta-analyses include RCTs of adults with obesity who do and do not have obesity-related diseases and complications, and other network meta-analyses have reported similar results (2,3).

To date, phentermine has only been studied in short-term RCTs (28 weeks or less) (50,52–54); however, a 2019 observational study demonstrated that long-term phentermine use was associated with significant weight reduction: individuals prescribed the medication for $\geq$12 months experienced a 7.4% greater weight reduction compared with those with $\leq$3 months (55). This analysis also showed no significant increase in the risks of cardiovascular disease or death among individuals prescribed phentermine long term. In individuals without cardiovascular disease, serious psychiatric disease, or substance use disorder, phentermine monotherapy may be an effective and safe option for achieving sustained weight reduction, with the caveat that no long-term efficacy and safety trial data currently exist (56,57). Long-term phentermine monotherapy is an off-label use, as this medication is only FDA-approved for short-term use, and health care professionals should be aware that some geographic areas may legally restrict this approach. Long-term phentermine monotherapy may be considered after discussion of the benefits and risks of all obesity



FIGURE 2.1 Obesity medications among adults without obesity-related diseases or complications. Among adults without obesity-related diseases or complications, obesity medications are indicated in adults with obesity. *The level of evidence ratings are identified in parentheses. Obesity medications are listed in relative order of benefit within each box where medications with greatest magnitude of benefit are listed first, although most obesity medications have not been compared in direct head-to-head trials. Categorization reflects expected average placebo-subtracted weight loss in meta-analyses to represent the weight-reducing effect of the obesity medication beyond that achieved with lifestyle change alone (51,52). Individual responses may vary. Given that obesity medications should be used in combination with lifestyle changes, the total anticipated weight reduction effect would be the combined effect of the obesity medication plus lifestyle (e.g., >13% loss for high weight-reducing effect obesity medication plus lifestyle). In meta-analyses, lifestyle counseling achieved 2.6% weight reduction (2); however, intensive behavioral therapy typically results in greater magnitude of weight reduction relative to lower intensity lifestyle counseling. Therefore, the combination of obesity medication with intensive behavioral therapy may result in greater total anticipated weight reduction effect. Of note, the maximum dose of semaglutide and liraglutide approved to treat obesity differs from the doses of these medications approved to treat type 2 diabetes. †To date, phentermine has only been studied in short-term RCTs (≤6 months duration). ‡Barriers to long-term use may include adverse medication effects, insurance coverage, out-of-pocket costs, etc.

medications, including those FDA-approved for long-term use. Phentermine is a schedule IV controlled substance, and therefore health care professionals should perform an in-person examination and evaluation, preferably with electrocardiogram, prior to prescribing this medication. The starting dose of phentermine should be 15 mg daily or less, and the dose may be increased based on tolerability and treatment response. Health care professionals should consider monthly follow-up, including monitoring of blood pressure and pulse, until the phentermine dose is stable, with follow-up every 3–6 months for long-term treatment to maintain health goals. Phentermine is one of the most prescribed obesity medications in the U.S. (58).

Prior research has shown that adverse effects from obesity medications contribute to individuals discontinuing the medication (2,59). Therefore, health care professionals should advise individuals of the adverse effects associated with each obesity medication and discuss strategies to



FIGURE 2.2 Obesity medications among adults with obesity-related diseases and complications. Among adults with obesity-related diseases or complications, obesity medications are indicated in adults with overweight or obesity. *Obesity medications are identified as "demonstrated benefit" if there is A-level evidence of benefit in the specified outcome for each obesity-related disease or complication. Obesity medications with B- or C-level evidence for these outcomes are identified as having "potential benefit." Obesity medications are listed in relative order of benefit where medications with greatest benefit are listed first; to date, no head-to-head trials have compared these outcomes in obesity medications. The level of evidence ratings are identified in parentheses. †Barriers to long-term use may include adverse medication effects, insurance coverage, out-of-pocket costs, etc. AHI, apnea hypopnea index; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HTN, hypertension; MACE, major adverse cardiovascular events; MASH, metabolic dysfunction–associated steatohepatitis; OA, osteoarthritis; OSA, obstructive sleep apnea; PreDM, prediabetes; T2D, type 2 diabetes.

minimize or manage these effects (Table 2.1). For example, glucagon-like peptide 1 receptor agonists (GLP-1RAs) and a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist (dual GIP/GLP-1RA) are associated with gastrointestinal adverse effects including nausea, diarrhea, constipation, and dyspepsia (60–62), which may be managed by decreasing portion sizes, decreasing intake of high-fat foods, increasing intake of high-fiber foods, avoiding long intervals between meals, and eating the last meal ≥2 h before bedtime (63,64).

For an individual with obesity who does not have any obesity-related diseases or complications, the primary treatment goal is to prevent the development of these

conditions (Fig. 2.1). Health care professionals should perform a comprehensive medical evaluation before selecting a medication to ensure safety and efficacy. Pharmacotherapy is an important tool for managing obesity, particularly when lifestyle interventions alone are insufficient to achieve and sustain weight reduction (53). The amount of weight reduction necessary to prevent obesity-related diseases and complications varies from person to person, and the health care professional should consider cost, access, tolerability, and individual preferences in the decision-making. Current costs of each obesity medication are summarized in Table 2.4.

Prediabetes

In individuals with obesity, weight reduction is highly effective in preventing or delaying progression to type 2 diabetes (T2D), particularly in high-risk people with prediabetes or metabolic syndrome. T2D prevention is dependent on weight-reduction magnitude, as evident from the Diabetes Prevention Program that demonstrated near-maximal T2D prevention was observed at ∼10% weight reduction with lifestyle intervention (65). Figure 2.2 and Table 2.5 summarize outcomes of obesity medications among individuals with prediabetes. For example, an RCT employing phentermine-topiramate achieved 10% weight reduction and reduced incident T2D by 79% (66), which is a relatively similar T2D reduction to that achieved with metabolic-bariatric surgery (67,68). Orlistat also reduces incident T2D by 37% (69).

More recent studies with GLP-1RA obesity medications are consistent with a weight-reduction goal of ∼10% to prevent T2D progression. An RCT of liraglutide 3 mg produced 6.1% weight reduction and reduced T2D progression by 79% (70). Semaglutide 2.4 mg was highly effective in converting prediabetes to normoglycemia (71), and 9.7% weight reduction with semaglutide was associated with 73% reduction in risk of developing T2D compared with placebo over ∼4 years of observation in the SELECT RCT (72). Tirzepatide 15 mg led to a 93% T2D reduction associated with 19.7% weight reduction in the 3-year SURMOUNT-1 extension study (73); this T2D prevention benefit may reflect incretin effects of the GLP-1 component and GIP bioeffects in addition to weight reduction (74,75).

Type 2 Diabetes

While the relationship between obesity and pathogenesis of T2D is complex, weight reduction represents highly effective therapy for both glycemic management and amelioration of obesity-related diseases and complications. The value of weight reduction as a primary treatment approach in T2D, whether at initial diagnosis or in conjunction with glucose-lowering therapy at any time over the disease course, is emphasized in the ADA's "Standards of Care in Diabetes" (76). Health care professionals should be aware that people with T2D typically lose less weight than individuals without this diagnosis (77). All obesity medications FDA-approved for long-term treatment have been studied in RCTs that enrolled people with T2D (Fig. 2.2 and Table 2.5) (2,78–83). Weight reduction with obesity medication consistently lowers A1C and reduces the need for diabetes medications when compared with lifestyle alone (78–84). With obesity medications, individuals with T2D and obesity also experience blood pressure reductions, improvements in lipids, decreased hepatic transaminases, and improvements in cardiovascular risk biomarkers. Three medications approved for obesity (i.e., liraglutide, semaglutide, and tirzepatide) also have an indication for glycemic management (84–86), although maximum approved doses for T2D are lower for liraglutide and semaglutide than approved doses for obesity.

Given their weight reduction and glucose-lowering benefits, health care professionals should strongly consider a GLP-1RA or dual GIP/GLP-1RA obesity medication as part of the treatment plan in people with obesity and T2D. In the SURMOUNT-2 RCT involving people with T2D and obesity, tirzepatide 15 mg produced weight reduction of 14.7% and resulted in a 2.1% A1C reduction, with nearly half of people achieving normal A1C values (<5.7%) (78). In the STEP 2 RCT, semaglutide 2.4 mg resulted in a 9.6% weight reduction and A1C lowering of 1.6% (79). The SCALE Diabetes trial in people with obesity and T2D demonstrated that liraglutide 3 mg produced a 6.0% weight reduction and 1.3% A1C reduction (80). Severe hypoglycemic episodes were uncommon in individuals randomized to tirzepatide, semaglutide, and liraglutide in these trials (78–80).

If a GLP-1RA or dual GIP/GLP-1RA obesity medication cannot be used, then other obesity medications may be considered. In people with T2D and obesity, phentermine-topiramate 15/92 mg resulted in 9.4% weight reduction and A1C lowering of 1.6% (81). Naltrexone-bupropion 32/360 mg led to a 5% weight reduction in people with obesity and T2D and A1C lowering of 0.6% (82). Orlistat resulted in 6.2% weight reduction and 0.3% A1C decrease in this population (83).

Hypertension

Hypertension is an obesity-related disease (87,88), and one of the benefits of weight reduction is lowering blood pressure. Greater weight reduction leads to greater improvements in systolic and diastolic blood pressure with intensive lifestyle intervention (45). Blood pressure lowering in individuals with and without hypertension is observed with most obesity medications (Fig. 2.2 and Table 2.5) (18,41,42,89–94). For example, tirzepatide 15 mg reduced systolic and diastolic blood pressure by 7.2 mmHg and 4.8 mmHg, respectively (18), and a substudy using 24-h ambulatory monitoring found that tirzepatide substantially reduced daytime and nighttime blood pressures in individuals with elevated baseline systolic pressure (95). It should

TABLE 2.3 Mechanisms of action and dosing of obesity medications for adults

Medication (route)	Mechanisms of action	Available doses	Manufacturer-recommended dose-escalation schedule*	Maximum approved dose	Dose adjustment in renal impairment†	Impact on oral contraceptive efficacy
Orlistat (oral)	Intestinal lipase inhibitor	120 mg 60 mg (OTC)	None	120 mg TID	Not required	None
Phentermine (oral)	Sympathomimetic amine	8 mg 15 mg 30 mg 37.5 mg	None	8 mg TID 37.5 mg daily	eGFR 15–29 mL/min: 15 mg daily max	None
Phentermine-topiramate (oral)	Sympathomimetic amine combined with GABA augmentation	3.75/23 mg 7.5/46 mg 11.25/69 mg 15/92 mg	Week 1–2: 3.75/23 mg daily Week 3–13: 7.5/46 mg daily Week 14–15: 11.25/69 mg daily‡ Week 16+: 15/92 mg daily	15/92 mg daily	CrCl <50: 7.5/46 mg daily max	Altered bioavailability to OCP components that may cause irregular bleeding
Naltrexone-bupropion (oral)	POMC neuron stimulation via dopamine/norepinephrine reuptake inhibitor and opioid receptor antagonist	8/90 mg	Week 1: 1 tablet daily Week 2: 1 tablet BID Week 3: 2 tablets QAM and 1 tablet QPM Week 4+: 2 tablets BID	16/180 mg BID	Moderate to severe renal impairment: 8/90 mg twice daily max	None
Liraglutide (SQ)	GLP-1 receptor agonist	18 mg/3 mL pen	Week 1: 0.6 mg SQ daily Week 2: 1.2 mg SQ daily Week 3: 1.8 mg SQ daily Week 4: 2.4 mg SQ daily Week 5+: 3.0 mg SQ daily	3.0 mg daily	Not required	None‖
Semaglutide (SQ)	GLP-1 receptor agonist	0.25 mg/0.5 mL pen 0.5 mg/0.5 mL pen 1 mg/0.5 mL pen 1.7 mg/0.75 mL pen 2.4 mg/0.75 mL pen	Week 1–4: 0.25 mg SQ weekly Week 5–8: 0.5 mg SQ weekly Week 9–12: 1 mg SQ weekly Week 13–16: 1.7 mg SQ weekly§ Week 17+: 2.4 mg SQ weekly	2.4 mg weekly	Not required	None‖
Tirzepatide (SQ)	Dual GIP and GLP-1 receptor agonist	2.5 mg/0.5 mL pen or vial 5 mg/0.5 mL pen or vial 7.5 mg/0.5 mL pen or vial 10 mg/0.5 mL pen or vial 12.5 mg/0.5 mL pen or vial 15 mg/0.5 mL pen or vial	Week 1–4: 2.5 mg SQ weekly Week 5–8: 5 mg SQ weekly§ Week 9–12: 7.5 mg SQ weekly Week 13–16: 10 mg SQ weekly§ Week 17–20: 12.5 mg SQ weekly Week 21+: 15 mg SQ weekly	15 mg weekly	Not required	Significant interaction with OCPs¶

BID, twice a day; CrCl, creatinine clearance; eGFR, estimate glomerular filtration rate; GABA, γ-aminobutyric acid; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide 1; OCP, oral contraceptive pill; OTC, over the counter; POMC, proopiomelanocortin; QAM, every morning; QPM, every evening; SQ, subcutaneous; TID, three times a day. *In clinical practice, dose escalation or de-escalation should be tailored to individual treatment response balancing benefits and adverse effects. Information provided is based on manufacturer-suggested dose-escalation schedule; dose-escalation schedule and maintenance dose is often modified based on individual response and goals. †Information is adapted from manufacturer-suggested renal dose adjustment. For individuals with severe renal impairment (eGFR <30 mL/min) or end-stage kidney disease, caution and close monitoring should occur if orlistat, liraglutide, semaglutide, or tirzepatide is used. Phentermine, phentermine-topiramate, and naltrexone-bupropion should be avoided in these individuals. ‡For individuals who achieve ≥3% weight reduction at week 14, phentermine-topiramate may be continued at 7.5/46 mg daily dose. §Indicated doses may also be maintenance doses per manufacturer guidelines. ‖No effect was found on bioavailability of OCP; however, concern has been raised about how delayed gastric emptying from the medication may affect efficacy of OCPs. ¶Advise individuals using oral hormonal contraceptives to switch to a nonoral contraceptive method, or add a barrier method of contraception, for 4 weeks after initiation with tirzepatide and for 4 weeks after each dose escalation.

TABLE 2.4 Median monthly AWP and NADAC of maximum dose of obesity medications*

Medication	Maximum approved dose	Median AWP for 30-day supply† (range)	Median NADAC for 30-day supply† (range)
Orlistat‡	120 mg TID	$651 ($520–$781)	$518 ($416–$619)
Phentermine	37.5 mg daily	$43 ($3–$56)	$2 ($2–$3)
Phentermine-topiramate	15/92 mg daily	$251	NA
Naltrexone-bupropion	16/180 mg BID	$750	NA
Liraglutide	3 mg daily	$1,619	$1,304
Semaglutide	2.4 mg weekly	$1,619	$1,304
Tirzepatide	15 mg weekly	$1,304§	$1,052§

AWP, average wholesale price; BID, twice daily; NA, data not available; NADAC, National Average Drug Acquisition Cost; TID, three times daily. *The costs listed in this table are representative of costs at a national level. These costs may not be representative of an individual's cost and do not account for medication coverage, available discounts from manufacturers, or direct-to-consumer pricing. AWP (252) and NADAC (253) prices are for 30-day supply of maximum or maintenance dose as of 2 July 2025. †Price ranges provided when multiple products (e.g., one or more generic products in addition to the branded product) are commercially available. ‡Orlistat is also available over the counter with maximum approved dose of 60 mg TID. Mean AWP for a 30-day supply is $58 (range $41–$90), and median NADAC is unavailable. §Price data listed is for tirzepatide pens only.

be noted that tirzepatide, semaglutide, liraglutide, and phentermine-topiramate, on average, cause small increases in resting heart rate (~2–4 bpm), although some individuals may experience larger increases (~10–20 bpm). This heart rate change is not clinically detrimental to most individuals, as the rate-pressure product (heart rate × systolic blood pressure) (96–98), which indicates workload on the heart, remains favorable due to blood pressure reductions. Health care professionals should be aware that naltrexone-bupropion does not reduce blood pressure commensurate with weight reduction (89), and both naltrexone-bupropion and phentermine are contraindicated in individuals with uncontrolled hypertension.

Atherosclerotic Cardiovascular Disease

Obesity contributes to atherosclerotic cardiovascular disease (ASCVD) development through multiple mechanisms (99), and the duration of obesity and visceral adiposity are strong predictors of coronary artery disease in epidemiologic studies (100). The magnitude of weight reduction achieved may be particularly critical for ASCVD (99), as modest weight reduction with intensive lifestyle intervention did not reduce the rate of cardiovascular events in adults with T2D and obesity (101); a post hoc analysis of this RCT found that only participants who achieved ≥10% weight reduction had significant reductions in cardiovascular events (102). In adults with obesity and established ASCVD, the treatment plan should include a GLP-1RA with demonstrated benefits or dual GIP/GLP-1RA with potential benefits in reducing cardiovascular events as well as weight reduction (Fig. 2.2 and Table 2.5).

Semaglutide reduces cardiovascular events among high-risk individuals (e.g., those with prior ASCVD or T2D) (103). In the SELECT RCT, semaglutide 2.4 mg resulted in a 20% reduction in adverse cardiovascular outcomes (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with BMI ≥27 kg/m^2 and established cardiovascular disease without diabetes (4). Further, semaglutide produced durable weight reduction (104) and significantly reduced new-onset diabetes and a composite kidney outcome (driven by reductions in new-onset macroalbuminuria) (105). While a cardiovascular outcomes trial evaluating liraglutide 3.0 mg has not been performed, liraglutide 1.8 mg (T2D-approved dose) reduces cardiovascular events in people with T2D at increased cardiovascular risk, including among participants with obesity (5). Similar findings were observed with liraglutide 3.0 mg versus pooled comparators in the SCALE trials (HR 0.42; 95% CI 0.17–1.08) (106), but this analysis was underpowered due to low event rates.

A cardiovascular outcomes trial of dual GIP/GLP-1RA obesity medication has not yet been published; however, there is evidence to support potential ASCVD benefits. Tirzepatide has been shown to significantly improve cardiovascular risk factors (e.g., blood pressure, cholesterol, systemic inflammation, and glycemic management) in people with obesity (18,107). In a SURMOUNT-1 trial post hoc analysis, tirzepatide significantly reduced the predicted 10-year risk of ASCVD events compared with placebo (108). Moreover, in a prespecified participant-level pooled analysis of the SURPASS program, tirzepatide did not increase the risk of major adverse cardiovascular events in people with T2D versus pooled comparators (HR 0.80; 95% CI 0.57–1.11) (109).

The LIGHT trial, which randomized people with BMI 27–50 kg/m^2 at increased cardiovascular risk to naltrexone-bupropion, was designed to evaluate cardiovascular outcomes. In the primary analysis (conducted after 50% of planned events), naltrexone-bupropion did not reduce major adverse cardiovascular events compared with placebo (110). However, due to unplanned early termination after public release of confidential interim data, the LIGHT trial was unable to rigorously establish the safety and efficacy of naltrexone-bupropion compared with placebo. Moreover, most participants permanently

TABLE 2.5 Summary of key evidence to inform obesity medication selection, by populations with specific obesity-related diseases and complications*

Obesity medication	Mean weight change with obesity medication* (time point)	Select outcomes relevant to population
Adults with obesity and prediabetes: progression to type 2 diabetes (Recommendation 2.7)		
Tirzepatide	−12.3% to −19.7% (176 weeks)	• 1.3% TZP vs. 13.3% PBO received a diagnosis of T2D at 176 weeks (HR 0.07; 95% CI 0.0–0.1; *P* <0.001) (73)
Semaglutide	−13.9% (52 weeks)	• 1% SEMA vs. 3% PBO progressed to T2D at 52 weeks (71) • 1.5% SEMA vs. 6.9% PBO progressed to T2D at 156 weeks (*P* <0.0001) (72)
Phentermine-topiramate	−10.9% to −12.1% (108 weeks)	• Annualized incidence rates for progression to T2D: 1.3% in PHEN-TOP 15 mg/92 mg, 1.8% in PHEN-TOP 7.5 mg/46 mg, and 6.1% in PBO at 108 weeks (66)
Liraglutide	−6.1% (160 weeks)	• 2% LIRA vs. 6% PBO were diagnosed with T2D at 160 weeks (HR 0.21; 95% CI 0.13–0.34; *P* <0.0001) (70)
Orlistat	−5.3% (208 weeks)	• Cumulative incidence of T2D was 6.2% ORL vs. 9.0% PBO at 208 weeks (HR 0.63; 95% CI 0.46–0.86) (69)
Adults with obesity and type 2 diabetes: glucose-lowering efficacy (Recommendation 2.8)		
Tirzepatide	−7.9% to −11.0% (40 weeks) −12.8% to −14.7% (72 weeks)	Mean A1C change • −1.9% to −2.1% TZP vs. +0.0% PBO at 40 weeks (84) • −2.1% TZP vs.−0.5% PBO at 72 weeks (78) Achieved A1C <7% • 87% to 92% TZP vs. 19% with PBO at 40 weeks (84) • Over 80% TZP vs. 36% PBO at 72 weeks (78)
Semaglutide	−4.2% to −4.7% (30 weeks) −7.0% to −9.6% (68 weeks)	Mean A1C change • −1.5% to −1.6% SEMA vs.−0.0% PBO at 30 weeks (85) • −1.5% to −1.6% SEMA vs.−0.4% PBO at 68 weeks (79) Achieved A1C <7% • 72% to 74% SEMA vs. 25% PBO at 40 weeks (85) • 72.3% to 78.5% SEMA vs. 26.5% PBO at 68 weeks (79)
Liraglutide	−4.7% to −6.0% (56 weeks)	Mean A1C change • −0.7% to −1.0% LIRA vs. +0.1% PBO at 26 weeks (254) • −1.1% to −1.3% LIRA −0.3% PBO at 56 weeks (*P* < 0.001) (80) Achieved A1C <7% • 66.7% to 69.2% LIRA vs. 27.2% PBO at 56 weeks (*P* < 0.001) (80)
Phentermine-topiramate	−9.4% (56 weeks)	Mean A1C change • −1.6% PHEN-TOP vs.−1.2% PBO at 56 weeks (*P* = 0.0381) (81) Achieved A1C <7% • 51% to 63% PHEN-TOP vs. 39% to 40% PBO at 56 weeks (81)
Naltrexone-bupropion	−5.0% (56 weeks)	Mean A1C change • −0.6% NB vs.−0.1% PBO at 56 weeks (82) Achieved A1C <7% • 44.1% NB vs. 26.3% PBO at 56 weeks (82)
Orlistat	−6.2% (52 weeks)	Mean A1C change • −0.3% ORL vs. +0.2% PBO at 52 weeks (83)
Adults with hypertension: blood pressure reduction (Recommendation 2.9)		
Tirzepatide	−15.0% to −20.9% (72 weeks)	Mean SBP change • −7.2 mmHg TZP and −1.0 mmHg PBO at 72 weeks (18) • PBO-adjusted ABPM change of −7.4 mmHg for TZP 5 mg, −10.6 mmHg for TZP 10 mg, and −8.0 mmHg for TZP 15 mg on ABPM at 36 weeks (95) Mean DBP change • −4.8 mmHg TZP and −0.8 mmHg PBO groups at 72 weeks (18)
Semaglutide	−14.9% (68 weeks)	Mean SBP change • −6.2 mmHg SEMA and −1.1 mmHg PBO at 68 weeks (*P* <0.001) (42) Mean DBP change • −2.8 mmHg SEMA and −0.4 mmHg PBO at 68 weeks (42)

Continued on p. 14 »

« *Continued from p. 13*

TABLE 2.5 Summary of key evidence to inform obesity medication selection, by populations with specific obesity-related diseases and complications* (Continued)

Obesity medication	Mean weight change with obesity medication* (time point)	Select outcomes relevant to population
Orlistat	−5.3% (208 weeks)	Mean SBP change • −7.3 mmHg ORL vs.−5.2 mmHg PBO at 52 weeks ($P < 0.01$); −4.9 mmHg ORL vs. −3.4 mmHg PBO at 208 weeks ($P < 0.01$) (69) Mean DBP change • −3.6 mmHg ORL vs.−2.6 mmHg PBO at 52 weeks ($P < 0.01$); −2.6 mmHg ORL vs. −1.9 mmHg PBO at 208 weeks ($P < 0.01$) (69)
Phentermine- topiramate	−7.8% to −9.89% (56 weeks)	Mean SBP change • −5.6 mmHg PHEN-TOP 15/92 mg vs.−2.4 mmHg PBO at 56 weeks ($P < 0.001$) (40) Mean DBP change • 3.8 mmHg PHEN-TOP 15/92 mg vs.−2.7 mmHg PBO at 56 weeks ($P = 0.003$) (40)
Liraglutide	−8.0% (56 weeks)	Mean SBP change • −4.2 mmHg LIRA and −1.5 mmHg PBO at 56 weeks ($P < 0.001$) (41) Mean DBP change • −2.6 mmHg LIRA and −1.9 mmHg PBO groups at 56 weeks ($P < 0.001$) (41)
Adults with obesity and established atherosclerotic cardiovascular disease: reduce cardiovascular events (Recommendation 2.10)		
Semaglutide	−9.4% (104 weeks)	• MACE HR 0.80 (95% CI 0.72–0.90; $P < 0.001$) SEMA vs. PBO over a mean follow-up of 40 months (4)
Liraglutide	−5.7% to −9.2% (≥32 weeks)	• MACE HR 0.42 (95% CI 0.17–1.08) LIRA vs. comparators ≥32 weeks (106) • MACE HR 0.87 (95% CI 0.78–0.97; $P < 0.001$) for liraglutide vs. PBO over a median follow-up of 3.8 years (5)
Tirzepatide	−11.9% to −17.8% (72 weeks)	• Change in 10-year ASCVD risk score −23.5% to −16.4% TZP vs. +12.7% PBO at 72 weeks ($P < 0.001$) (108)
Adults with obesity and heart failure with preserved ejection fraction: reduce heart failure symptoms or events (Recommendation 2.11)		
Semaglutide	−9.8% to −13.3% (52 weeks)	Heart failure symptoms • Mean KCCQ-CSS change 16.6 SEMA vs. 8.7 PBO at 52 weeks ($P < 0.001$) (47) • Mean KCCQ-CSS change 13.7 SEMA vs. 6.4 PBO at 52 weeks ($P < 0.001$) (255) • Mean KCCQ-CSS change 15.0 SEMA vs. 7.5 PBO at 52 weeks ($P < 0.0001$) (118) Heart failure events • SELECT trial ○ Composite HF outcome HR 0.82 (95% CI 0.71–0.96) SEMA vs. PBO over mean follow-up of 40 months (4) • Pooled analysis (SELECT, FLOW, STEP-HFpEF, STEP-HFpEF DM) ○ CV death or HF event HR 0.69 (95% CI 0.53–0.89; $P = 0.0045$) SEMA vs. PBO at ≥52 weeks (121) ○ Worsening HF event HR 0.59 (95% CI 0.41–0.82; $P = 0.0019$) SEMA vs. PBO at ≥52 weeks (121)
Tirzepatide	−13.9% (52 weeks)	Heart failure symptoms • Mean KCCQ-CSS change 19.5 TZP vs. 12.7 PBO at 52 weeks ($P < 0.001$) (48) • Between-group median KCCQ-CSS difference 6.9 favoring TZP over PBO at 52 weeks ($P < 0.001$) (123) Heart failure events • CV death or worsening HF event (HF hospitalization, intravenous drugs in an urgent care setting, or intensification of oral diuretic therapy) HR 0.62 (95% CI 0.41–0.95; $P = 0.026$) TZP vs. PBO over a median follow up of 104 weeks (48)

Continued on p. 15 »

« Continued from p. 14

TABLE 2.5 Summary of key evidence to inform obesity medication selection, by populations with specific obesity-related diseases and complications* (Continued)

Obesity medication	Mean weight change with obesity medication* (time point)	Select outcomes relevant to population
Adults with obesity and metabolic dysfunction-associated steatohepatitis: benefits for MASH (Recommendation 2.12)		
Semaglutide	−8.8% (48 weeks) −10.5% (72 weeks)	• 62.9% SEMA met criteria for steatohepatitis resolution without worsening of fibrosis vs. 34.3% PBO at 72 weeks (95% CI 21.1–36.2; $P < 0.001$) (7) • 36.8% SEMA met criteria for fibrosis resolution without worsening of steatohepatitis vs. 22.4% PBO at 72 weeks (95% CI 7.5–21.3; $P < 0.001$) (7) • 11% (5/47) SEMA had improvement in ≥1 stage of fibrosis without worsening of MASH vs. 29% (7/24) with PBO at 48 weeks (129)
Tirzepatide	−10.7% to −15.6% (52 weeks)	• 44% to 62% of TZP met criteria for resolution of MASH without worsening of fibrosis vs. 10% PBO at 52 weeks ($P < 0.001$) (46)
Liraglutide	−5.5% (48 weeks)	• 39% LIRA met criteria for MASH resolution vs. 9% PBO at 48 weeks ($P = 0.019$) (131) • 9% LIRA had progression of fibrosis vs. 36% PBO at 48 weeks ($P = 0.04$) (131)
Adults with obesity and obstructive sleep apnea: benefits for sleep apnea (Recommendation 2.13)		
Tirzepatide	−17.7% to −19.6% (52 weeks)	• Mean AHI change −25.3 events/h TZP vs. −5.3 events/h with PBO at 52 weeks among participants not using PAP ($P < 0.001$) (6) • Mean AHI change −29.3 events/h TZP vs. −5.5 events/h with PBO at 52 weeks among participants using PAP ($P < 0.001$) (6)
Liraglutide	−5.7% (32 weeks)	• Mean AHI change of −12.2 events/h with LIRA vs. −6.1 events/h with PBO at 32 weeks ($P = 0.0150$) (140)
Phentermine- topiramate	−10.3% (28 weeks)	• Mean AHI change of −31.5 events/h with PHEN-TOP vs. −16.6 events/h with PBO at 28 weeks ($P = 0.0084$) (139)
Adults with obesity and osteoarthritis: benefits for osteoarthritis symptoms (Recommendation 2.14)		
Semaglutide	−13.7% (68 weeks)	• Mean change −41.7 points on WOMAC pain score with SEMA vs. −27.5 points with PBO at 68 weeks ($P < 0.001$) (49)
Liraglutide	−6.6% (52 weeks)	• No differences in daily physical activity time assessed via accelerometer between LIRA and PBO at 52 weeks after achieving ≥5% weight loss and knee pain reduction with 8-week very-low-calorie meal plan before randomization (147) • No difference in KOOS pain score between LIRA and PBO at 52 weeks (256); significant between-group difference in KOOS function subscale (3.8 points; 95% CI 0.9–6.7; $P = 0.01$) (147)
Tirzepatide	Not reported	• In a retrospective cohort, TZP was associated with a significantly lower risk of new osteoarthritis diagnosis compared with SEMA (HR 0.57; 95% CI 0.50–0.65; $P < 0.0001$) (148)

A1C, hemoglobin A1c; ABPM, ambulatory blood pressure monitoring; AHI, apnea-hypopnea index; ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; DBP, diastolic blood pressure; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HR, hazard ratio; KCCQ-CSS, Kansas City Cardiomyopathy Questionnaire clinical summary score; KOOS, Knee injury and Osteoarthritis Outcome Score; LIRA, liraglutide; MACE, major adverse cardiovascular event (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke); MASH, metabolic dysfunction–associated steatohepatitis; NB, naltrexone-bupropion; ORL, orlistat; PAP, positive airway pressure; PBO, placebo; PHEN-TOP, phentermine-topiramate; SBP, systolic blood pressure; SEMA, semaglutide; T2D, type 2 diabetes; TZP, tirzepatide; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index. *Of note, phentermine is not included in this table, as all outcomes reported require long-term trials and phentermine has only been studied in short-term RCTs (28 weeks or less) to date.

discontinued study medication by 1-year post-randomization. There are no cardiovascular outcomes trials for orlistat, phentermine, or phentermine-topiramate.

Heart Failure With Preserved Ejection Fraction

Obesity is a leading driver of heart failure with preserved ejection fraction (HFpEF) onset and progression (111–115), and individuals with obesity and HFpEF display unique clinicopathological features (e.g., increased plasma volume and greater cardiac remodeling) when compared with individuals with HFpEF without obesity (116). Modest weight reduction among individuals with obesity and HFpEF through lifestyle change improves aerobic capacity, New York Heart Association functional class, and quality of life (117). In adults with obesity and HFpEF, the treatment plan should include a GLP-1RA or dual GIP/GLP-1RA with demonstrated improvements in heart failure (HF)-related symptoms or events (Fig. 2.2 and Table 2.5).

In the STEP-HFpEF RCT, semaglutide 2.4 mg significantly improved HF-related symptoms and functional limitations and reduced body weight (11% placebo-subtracted reduction) in people with BMI ≥30 kg/m^2 and chronic symptomatic HF with left ventricular ejection fraction (LVEF) ≥45% (46). In pooled analyses, semaglutide improved exercise function and natriuretic peptide levels (118), reduced diuretic requirements (119), and attenuated adverse myocardial remodeling (120). In a prespecified pooled analysis of the STEP-HFpEF Program, SELECT, and FLOW trials, semaglutide reduced cardiovascular death or HF events by 31% compared with placebo in participants with HF and LVEF ≥40% (121).

Tirzepatide has also been shown to reduce HF events in people with obesity and stable chronic HFpEF. Among individuals with BMI ≥30 kg/m^2 and HF with LVEF ≥50% enrolled in the SUMMIT RCT, tirzepatide improved HF-related health status and reduced the rate of cardiovascular death or a worsening HF event by 38% (48), although number of events was relatively low (36 with tirzepatide and 56 with placebo). Additional benefits on body weight (12% placebo-controlled reduction), exercise function, left ventricular mass, and paracardiac adipose tissue were also observed (122,123).

Metabolic Dysfunction–Associated Steatohepatitis

Metabolic dysfunction–associated steatohepatitis (MASH) is defined as the presence of steatohepatitis and no alcohol consumption or consumption in amounts unlikely to directly cause adverse liver outcomes (alcohol intake <20 g/day for women and <30 g/day for men) (124). Fibrosis is a predictor of disease progression (125) and is strongly linked to liver-related outcomes and death (126). Histologically, fibrosis is staged based on severity and distribution of scar tissue. Clinically significant fibrosis is defined as stage ≥F2 (moderate; sinusoidal and portal fibrosis), advanced fibrosis is F3 (i.e., bridging fibrosis, usually central-to-portal or central-to-central bridges), and F4 is cirrhosis (124). Among people with MASH, weight reduction of ≥10% may be needed to reverse steatohepatitis and improve fibrosis (127). In adults with obesity and MASH with moderate or advanced fibrosis, a GLP-1RA or dual GIP/GLP-1RA is preferred for obesity treatment because of the benefits or potential benefits on MASH (Fig. 2.2 and Table 2.5). While not specifically tested among individuals with MASH, health care professionals should be aware that the dose of naltrexone-bupropion needs to be adjusted in the setting of moderate hepatic impairment.

In a planned interim analysis of the ESSENCE RCT, semaglutide 2.4 mg significantly improved liver histology compared with placebo in individuals with biopsy-defined MASH and fibrosis stage F2 or F3 (7). Mean BMI was 34.3 kg/m^2 and 35.0 kg/m^2 in the semaglutide and placebo groups, respectively. Resolution of steatohepatitis with no worsening of liver fibrosis occurred in 62.9% of semaglutide participants and 34.3% of placebo; a reduction in liver fibrosis with no worsening of steatohepatitis was reported in 36.8% of semaglutide participants and 22.4% of placebo. Mean weight reduction with semaglutide was 10.5%. Prior phase 2 RCTs of semaglutide among individuals with MASH demonstrated significantly increased likelihood of MASH resolution (128) and improved cardiometabolic parameters (129). A meta-analysis (8 RCTs) demonstrated the short-term efficacy and safety of semaglutide in reducing liver fat content and improving liver stiffness compared with placebo (130). Less evidence exists regarding the use of liraglutide in MASH. In a phase 2 RCT of individuals with BMI ≥25 kg/m^2 and biopsy-confirmed MASH, liraglutide 1.8 mg demonstrated histological resolution of MASH and slowed fibrosis progression compared with placebo (131). Pilot studies comparing liraglutide 3 mg and structured lifestyle interventions found no significant difference in liver-related outcomes (132,133).

Tirzepatide has shown promise in treating MASH. In the phase 2 SYNERGY-NASH RCT, individuals with biopsy-confirmed MASH and stage F2 or F3 fibrosis were randomized to tirzepatide or placebo; 62% of the tirzepatide 15 mg group met criteria for resolution of MASH without worsening of fibrosis at 52 weeks compared with 10% in the placebo group (46). Overall, 51% of tirzepatide 15 mg participants improved at least one fibrosis stage without worsening of MASH as compared with 30% of placebo participants. Mean weight reduction was 15.6% with tirzepatide 15 mg. Lower doses of tirzepatide (5 mg and 10 mg) were also tested and showed benefits relative to placebo.

There currently is no direct evidence evaluating outcomes of the use of GLP-1RA or dual GIP/GLP-1RA obesity medications among individuals with obesity and metabolic dysfunction–associated steatotic liver disease (MASLD). These medications may be an effective and safe option for achieving sustained weight reduction in this population, given the demonstrated or potential benefits on MASH.

Obstructive Sleep Apnea

Obstructive sleep apnea (OSA) is an obesity-related disease characterized by partial or complete upper airway obstruction during sleep, leading to sleep fragmentation and hypoxemia (114). The prevalence of moderate-to-severe OSA, defined as AHI ≥15 events/h on polysomnography, increases with increasing body weight (134). OSA is associated with increased mortality in people with obesity (135,136). A 10% body weight reduction is associated with a 26% lower AHI (134). Weight reduction with intensive lifestyle intervention significantly decreases AHI and increases the likelihood of OSA remission (137,138).

Several obesity medications improve OSA in RCTs (Fig. 2.2 and Table 2.5) (6,139,140), and AHI reduction is strongly

related to the weight-reduction magnitude achieved with the obesity medication (139,140). To date, the greatest magnitude of benefit has been with tirzepatide. In the SURMOUNT-OSA trials, once-weekly tirzepatide (10 or 15 mg) significantly reduced AHI by more than 20 events/h compared with placebo in adults with obesity and moderate-to-severe OSA, among individuals treated with and without positive airway pressure (PAP) (6). Mean weight reduction with tirzepatide was ≥15%. Over 40% of SURMOUNT-OSA participants treated with tirzepatide experienced improvements in OSA severity to below typical thresholds to recommend PAP therapy. In short-term RCTs, phentermine-topiramate and liraglutide 3.0 mg reduced AHI by 15 and 6 events/h, respectively, compared with placebo among people with obesity and moderate-to-severe OSA (139,140). Inclusion of obesity medications may also have added benefits of improved systolic blood pressure, glycemia, and body weight reduction that individuals with OSA may be unlikely to achieve with PAP therapy alone (141,142). In addition to established OSA treatment approaches (e.g., PAP, airway stimulation, and splinting devices), the evidence supports obesity medications as part of the treatment plan for people with obesity and OSA.

Osteoarthritis

Osteoarthritis is an obesity-related disease, particularly knee osteoarthritis (143,144). Weight gains of ≥10% are associated with worsening pain and physical function (145), and weight reduction of similar magnitude may result in symptom improvements (146). In adults with obesity and moderate osteoarthritis, the treatment plan should prioritize a GLP-1RA or dual GIP/GLP-1RA with potential to improve osteoarthritis symptoms (Fig. 2.2 and Table 2.5). In a 68-week trial involving individuals with obesity and moderate knee osteoarthritis, semaglutide 2.4 mg significantly improved knee pain scores and reduced body weight compared with placebo (49); participants also experienced greater improvements in physical function. Less evidence exists regarding the use of liraglutide in osteoarthritis, which may only have modest benefits in physical function (147). A retrospective cohort study found that individuals prescribed semaglutide, liraglutide, or tirzepatide had a reduced risk of osteoarthritis diagnosis (148). Individuals prescribed tirzepatide had a significantly lower risk of osteoarthritis compared with individuals prescribed semaglutide or liraglutide.

Long-term Management of Obesity Medications

Recommendations

2.15 Obesity medications requiring dose escalation should be initiated at a low dose and uptitrated gradually, as needed, based on tolerability **A** and clinical response **E**.

2.16 Continue obesity medications after reaching treatment goals to maintain health benefits, as discontinuation often results in weight recurrence and worsening or reemergence of cardiometabolic risk factors or obesity-related diseases and complications **A**. The individualized maintenance dose should balance efficacy, health benefits, and tolerability and therefore may not necessarily be the maximum approved dose **A**.

2.17 In individuals with an inadequate response to current obesity medication, intensify treatment to improve outcomes. Dose escalation to maximum dose is recommended **A**. If maximum tolerable dose is already used, then consider switching to an alternative obesity medication **C**, adding intensive lifestyle therapy **B**, combining obesity medications **C**, or referring to metabolic-bariatric surgery **A**.

Gradual dose escalation is a critical strategy in obesity pharmacotherapy to optimize efficacy while improving tolerability. Many obesity medications have dose-dependent adverse effects, particularly gastrointestinal symptoms and neuropsychiatric effects (e.g., mood changes), that necessitate a stepwise escalation (39–42). For example, the SURMOUNT-1 RCT demonstrated that a 20-week dose-escalation period was essential to reaching the target therapeutic dose of tirzepatide while maintaining tolerability (18). Tirzepatide dose escalation often occurs more gradually in real-world clinical practice than what occurred in trials (149), reflecting the importance of adjustments based on individual response. Experiencing adverse effects has been significantly associated with obesity medication discontinuation (59). Individuals who experience early intolerance to high doses often benefit from remaining on low doses longer before advancing. Health care professionals may consider this approach to improve tolerability, particularly for older individuals, people with gastrointestinal sensitivities, or individuals with obesity-related diseases or complications.

As obesity is a chronic disease, long-term pharmacotherapy is typically needed after treatment goals are achieved to sustain benefits. Real-world evidence thus far shows that long-term use of obesity medications can maintain ≥10% weight reduction (150). Health care professionals and stakeholders who determine benefits coverage for health insurance should be aware that clinical trials show that discontinuation of obesity medications results in recurrence of most of the weight lost within 1 year and reversal of prior cardiometabolic improvements (107,151–153). Recent research has identified obesity medication costs as a factor contributing to individuals' discontinuing treatment (154). Loss of insurance coverage for obesity medications makes these treatments unaffordable for many individuals and contributes to their feelings of hopelessness, anger, and stigmatization (155). Obesity medications should be continued after reaching treatment and weight reduction goals to maintain health benefits and avoid weight recurrence (107,150,151,153,156).

The long-term maintenance dose of obesity medication should be tailored to optimize health benefits while minimizing adverse effects; multiple clinical trials have employed a "maximum tolerated dose" strategy to improve

medication-taking behavior (6,49,107). Beneficial outcomes can be achieved with a maintenance dose that is not the maximum dose. For example, a 20% cardiovascular risk reduction was noted in the SELECT trial despite flexible dosing of semaglutide (4). Health care professionals should take a practical approach of balancing risk and benefit to tailor the maintenance dose to each individual, which may include continuing obesity medication on the lowest effective dose (which may not be an FDA-approved maintenance dose), using intermittent therapy, switching to an alternative obesity medication, or stopping medication followed by close monitoring.

Inadequate Treatment Response

The response to all obesity medications is highly heterogeneous between individuals (157–159); therefore, health care professionals should regularly reassess their effectiveness in achieving treatment and weight reduction goals. For individuals with inadequate treatment response (e.g., not reaching intermediate treatment goals in 6 months or maintaining treatment goals), avoid treatment inertia by re-evaluating ongoing therapies and intensifying treatment with additional approaches. Increasing the dose of the current obesity medication to the maximum tolerated dose should be the first step (18,40,79,80). If the initial obesity medication or dose escalation of that medication is not well tolerated by the individual, then the health care professional should consider changing to a different obesity medication and discontinuing the ineffective medication. For individuals on a high-dose obesity medication that is ineffective, health care professionals may consider de-escalating medication dose slowly until reaching discontinuation to improve tolerability. Health care professional monitoring during de-escalation may be particularly important when discontinuing phentermine-topiramate and naltrexone-bupropion. Studies have shown that individuals who have inadequate response to one obesity medication can benefit from switching to another obesity medication (160–164). Beyond these approaches, health care professionals may also consider combining obesity medications, pairing obesity medication with intensive behavioral therapy/structured lifestyle program, or referring to metabolic-bariatric surgery.

Intensive behavioral therapy (IBT) or structured lifestyle programs comprise frequent clinic visits for nutrition, physical activity, and behavior change counseling to treat obesity. Multiple RCTs have demonstrated that combining IBT with obesity medication yields relatively greater weight reduction and health benefits (22,23,165,166). Combining IBT with select obesity medications (e.g., naltrexone-bupropion or liraglutide) is particularly beneficial for achieving greater magnitude of weight reduction relative to that achieved with lifestyle counseling (22,167). Adding IBT to semaglutide may have a diminished benefit relative to lifestyle counseling (24,42), although no trials have directly compared semaglutide with and without IBT. For example, one RCT found that naltrexone-bupropion with lifestyle counseling resulted in 6.1% weight reduction at 1 year (39) as compared with another RCT that found naltrexone-bupropion with IBT resulted in 9.3% weight reduction at 1 year (22). Similarly, an RCT found that tirzepatide with lifestyle counseling resulted in 20.9% weight reduction (18), while another RCT found that combining tirzepatide with IBT resulted in a 24.5% weight reduction (25). These results may suggest that combining obesity medication with IBT may improve outcomes relative to obesity medication with counseling alone. Referral should be considered where there is access to such programs.

For individuals who have a partial treatment response to the current obesity medication, it may be reasonable to combine this medication with another obesity medication. Health care professionals can target different weight-regulating pathways by combining obesity medications; in fact, weight reduction achieved by low-dose combination therapy may exceed that of high-dose monotherapy. For example, an RCT found that weight reduction achieved with phentermine-topiramate 7.5/46 mg was greater than phentermine 15 mg alone (10.4% vs. 7.4%, respectively) (50). Among individuals with T2D, the addition of naltrexone-bupropion to a GLP-1RA resulted in 5.2% greater weight reduction than that for individuals on placebo and GLP-1RA (168). However, a small pilot study found that the addition of phentermine to liraglutide did not produce additional clinically meaningful weight reduction in individuals who had already lost 12.6% of initial weight with liraglutide alone (169). The use of multiple obesity medications for chronic weight management mirrors treatment paradigms established for other chronic diseases, and this approach is also supported by long-term data in retrospective cohorts (150,156). However, there are no RCTs examining how to best escalate therapy for individuals with inadequate treatment response.

Metabolic-bariatric surgery should be offered to eligible individuals with inadequate treatment response to lifestyle modification and pharmacotherapy. Metabolic-bariatric surgery produces substantial weight reduction and achieves multiple health benefits including reduced blood pressure (170), improved glycemia among people with T2D (171), and reduced cardiovascular events (172). In addition, several studies have shown the benefit and safety of adding obesity medication after an individual has undergone metabolic-bariatric surgery (173–175). Therefore, obesity medications may also be added to augment weight reduction and health benefits in individuals who have undergone surgery where a weight plateau occurs before achieving their treatment goals or who are experiencing weight recurrence. Health care professionals should be aware of nonsurgical procedures to treat obesity, and a future section of the "Standards of Care for Overweight and Obesity" will provide recommendations regarding surgical and nonsurgical procedures to treat obesity.

Lifestyle Intervention With Obesity Medications

Recommendations

2.18 Nutrition recommendations should be tailored to individuals' preferences and nutritional needs **C**. Consider referral to a registered dietitian nutritionist **A**.

2.19 Counsel and regularly monitor individuals using obesity medications to ensure adequate nutritional intake, with particular attention to preventing protein insufficiency and micronutrient deficiencies during the active phase of weight reduction **E**.

2.20 Counsel individuals treated with obesity medications on the need for adequate protein intake **A** and muscle-strengthening activities **A** to minimize muscle loss that occurs with weight reduction.

When making nutrition recommendations, health care professionals should consider an individual's medical history, dietary intake and nutritional status, social determinants of health, personal values, and preferences. A meta-analysis concluded that personalized nutrition interventions are more effective at improving dietary intake than usual care, with mixed improvements in weight and waist circumference (16 studies) (176); however, another meta-analysis found that participant choice in dietary intervention did not confer a weight reduction benefit (9 studies) (177). Given that in-depth nutritional counseling may be challenging in clinical practice (178–180), referral to a registered dietitian nutritionist (RDN) for nutritional guidance should be considered for people prescribed obesity medications. RDNs use medical nutrition therapy—a counseling process that includes nutritional assessment, diagnosis, intervention, and monitoring and typically results in the prevention, delay, or management of disease (181). RDN-delivered obesity interventions improve BMI, waist circumference, blood pressure, and quality of life (182). In a systematic review (26 RCTs), RDN consultations were effective for improving nutritional quality as well as weight reduction and diabetes outcomes in the primary care setting (183). RDNs may also address other important behaviors including physical activity, sleep hygiene, stress management, problem solving, and goal setting (184).

Nutritional counseling is an important element in obesity management and improved health, particularly for people receiving obesity medications. Given the appetite-suppressing effects of many obesity medications, individuals may become vulnerable to inadequate nutrition due to diminished hunger, desire to eat small portions, or skipping meals. Nutritional counseling should prioritize consumption of nutrient-dense foods such as lean proteins, fruits, vegetables, whole grains, and healthy fats. A minimum of 60 g of protein daily should be recommended, although higher protein intake is often advised during weight reduction (1.2–1.6 g/kg per day) (185). An adequate daily intake of water 3.7 L (~13 cups) for men and 2.7 L (~9 cups) for women is also recommended (186). These protein and fluid goals should be modified among individuals with certain conditions, such as chronic kidney disease or heart failure. Eating patterns and nutritional adequacy should be assessed at each visit.

In general, adults with obesity have lower intakes of vitamins A, C, D, and E as well as calcium and magnesium compared with adults without obesity (187). The appetite suppressive effects of obesity medications lead to caloric reduction (188,189), and this reduced food consumption may be insufficient to meet essential micronutrient requirements in some individuals (190,191). Multivitamin mineral supplements may be considered for individuals who consume less than 1,200 kcal/day, exclude micronutrient-rich food groups from their usual intake (e.g., fruits and vegetables, whole grains, proteins, and nuts and seeds), are strict vegetarians, have underlying health conditions that impair nutrient absorption, are older (aged >50 years), or experience excessive weight reduction (192). Multivitamin mineral supplement use has been associated with lower risk of nutrient deficiencies (187,193). A daily multivitamin supplement is also recommended with orlistat therapy due to decreased absorption of fat-soluble vitamins (194). If nutritional intake remains inadequate due to obesity medication effects, the health care professional should consider dose reduction of the obesity medication.

All weight-reduction interventions are associated with reductions in fat mass and lean body mass (LBM), although the proportions of the two components vary over time and are determined by multiple factors (e.g., protein intake, exercise, sex, age, and baseline adiposity). In general, many nutrition intervention studies report that fat mass loss contributes to ~75% of body weight reduction, while LBM contributes to ~25% of body weight reduction (195). A concern over the risk of excessive skeletal muscle loss, a component of LBM, has been raised with the use of obesity medications, particularly medications that result in ≥15% weight reduction. In meta-analyses of GLP-1RA obesity medications, LBM loss accounts for 25% to 30% of total weight reduction (196,197). Similarly, a substudy of participants on tirzepatide found that LBM loss accounts for 25% of total weight reduction (198). Despite lean mass loss, questionnaires consistently demonstrate improvements in physical function and quality of life with weight reduction (199,200). However, older adults with obesity or adults with severe obesity-related diseases or complications may be vulnerable to later onset of sarcopenic obesity—a condition characterized by reduced skeletal muscle mass and function (201)—and lower bone mineral density due to excessive weight reduction. Health care professionals should consider regularly assessing muscle strength and function by one or more office-based techniques (e.g., chair-to-stand, handgrip, knee-extensor strength, and walk test) (201) and using functional instruments (e.g., SARC-F questionnaire) (202).

The treatment plan should emphasize optimizing protein intake through dietary counseling and supplementation (as needed), alongside resistance training to preserve

lean mass. A meta-analysis (47 RCTs) concluded that a protein intake exceeding 1.3 g/kg/day is beneficial in maintaining muscle mass during weight reduction among adults with obesity (203). However, other studies have found that its benefit on muscle strength is observed only when enhanced protein intake is combined with resistance training (204). A meta-analysis (114 RCTs) concluded that lean mass was maintained in interventions involving resistance training and caloric restriction, providing evidence that resistance-based exercise programs should be considered within multicomponent obesity treatment (205). Health care professionals should assess baseline activity levels and tailor recommendations to individual needs and context. Aerobic activity should also be included in a comprehensive treatment plan, given its cardiometabolic benefits. In a 1-year RCT, the combination of moderate-to-vigorous-intensity aerobic exercise and liraglutide was most beneficial in total body weight and percent fat loss relative to either treatment alone after an initial 8-week low calorie meal plan (21), and this combination also slowed weight recurrence and preserved bone health over an additional 1-year observational period (206,207).

Special Populations and Circumstances

Recommendations

2.21 Obesity medications should not be used during pregnancy, in individuals actively trying to become pregnant, or during lactation **E**.

2.22 Individuals of childbearing potential with obesity being considered for obesity medication should be counseled on contraception options **A** and the impact of some obesity medications on contraception efficacy **C** (Table 2.3).

2.23 Preconception planning should address the time frame for discontinuing obesity medications, and optimal treatment of obesity and related diseases and complications in preparation for pregnancy **E**.

2.24a Use of compounded products that are not approved by the FDA is not recommended due to uncertainty about their content and resulting concerns about safety, quality, and effectiveness **C**.

2.24b If an obesity medication is unavailable (e.g., in shortage), a switch to a different FDA-approved obesity medication is recommended, as clinically appropriate **E**. Upon resolution of the unavailability, reassess the appropriateness of resuming the original FDA-approved obesity medication **E**.

People of Childbearing Potential

All obesity medications are contraindicated in individuals who are pregnant or actively trying to conceive and are not recommended for use in individuals who are breastfeeding. Some obesity medications have been linked with fetal harm (208–210); notably, topiramate use during pregnancy is associated with major congential malformations (e.g., cleft lip/palate) and being small for gestational age in the fetus. Health care professionals should be aware of the FDA risk evaluation and mitigation strategy (REMS) for phentermine-topiramate. It is typically recommended that individuals of childbearing potential considering pregnancy stop obesity medications at least 2 months before a planned pregnancy, and intensification of lifestyle behavioral therapy may be needed to maintain weight.

While taking obesity medications, individuals of childbearing potential should receive counseling regarding the use of reliable methods of contraception (211,212). Health care professionals should be aware that weight reduction may increase fertility (213,214), so discussing a plan for reliable contraception should be performed in all people of childbearing potential. Some obesity medications may affect oral contraceptive medications (OCP) (Table 2.3), and individuals using OCPs should be advised of these risks. Tirzepatide has a clinically significant interaction with OCPs (215); therefore, it is recommended that individuals be advised to switch to a nonoral contraceptive method or add a barrier method of contraception for 4 weeks after tirzepatide initiation and for 4 weeks after each dose escalation (216). While bioavailability of OCPs has not been affected in studies with semaglutide and liraglutide (217,218), the delayed gastric emptying effect of these medications has been raised as a potential concern, although this effect typically diminishes over time. OCP bioavailability decreases with phentermine-topiramate; however, the degree of impact is not typically associated with increased risk of pregnancy with topiramate doses contained in this combination (219). Individuals taking OCPs and phentermine-topiramate may experience irregular bleeding (spotting) more frequently. Individuals should be advised to continue their OCP if spotting occurs and notify their health care professional if it is troubling (220). Bioavailability of OCPs is not affected by naltrexone-bupropion or orlistat (221,222).

Compounded Medications

Compounded medications do not undergo FDA review for safety, effectiveness, and quality before they are marketed (223). Recent studies have raised concerns about compounded obesity medications regarding impurities and adverse effects (224–228). The FDA considers the use of compounded obesity medications as risky, and the ADA discourages use of compounded GLP-1RA and dual GIP/GLP-1RA products due to safety, quality, and effectiveness concerns (229).

Clinical Practice Considerations With Obesity Medications

Recommendations

2.25 Clinical practices that are unable to implement the recommended infrastructure to support the pharmacologic treatment of obesity should consider referring people to

health care professionals with competency in obesity medicine **C**.

2.26 Health care professionals who prescribe obesity medications should be knowledgeable on their efficacy, indications, contraindications, adverse effects, benefits, and financial costs **C**.

2.27 Health care professionals should complete a comprehensive evaluation for obesity and obesity-related diseases and complications on each person before prescribing an obesity medication **E**.

2.28 Clinical practices should provide behavioral and lifestyle therapy for people prescribed obesity medications **A**. If in-house services are unavailable, refer to and collaborate with structured lifestyle programs, registered dietitian nutritionists, or other qualified health care professionals with expertise in delivering these interventions **A**.

2.29a After initiating an obesity medication, health care professionals should arrange for follow-up with individuals at least monthly during the first 3 months of treatment to support positive medication-taking behavior by assessing efficacy, managing adverse effects, and monitoring health status **B**. Follow-up can be delivered via telehealth or delivered by interprofessional members of the treatment team, such as registered dietitian nutritionists or nurses, to facilitate timely and effective care **C**.

2.29b For the remainder of the first year of obesity medication treatment, individuals should have follow-up visits at least every 3 months with trained health care professionals to continue monitoring efficacy and safety **C**. Thereafter, follow-up visit frequency may be reduced to every 6 months for long-term management **C**.

2.30 Clinical practices should consider allocating resources to manage prior authorizations for obesity medications as a strategy to reduce the likelihood that these requirements alter health care professionals' treatment decisions **E**.

Clinical practices may need to implement changes to support obesity medication prescribing (Recommendations 2.25–2.30) with the aims of ensuring safety, improving tolerability, and promoting medication-taking behavior. For clinical practices unable to make these changes, clinicians should consider referring people with obesity to health care professionals with competency in obesity medicine (230). Studies have found that obesity medicine physicians offer comprehensive obesity care, which includes lifestyle counseling, obesity medications, and perioperative care for metabolic-bariatric surgery (231–233). In a recent study, individuals who received care from an obesity medicine physician were significantly more likely to receive evidence-based obesity treatment and achieve greater weight reduction than matched control individuals (234).

Given that education and training on obesity treatment is lacking or insufficient in many medical schools, residency programs, and fellowships (235), many health care professionals are unfamiliar with obesity medications and have limited experience with their prescribing (236,237). Addressing this knowledge gap is important prior to integrating obesity medications into practice; health care professionals should understand the indications, contraindications, efficacy, benefits, adverse effects, and financial costs for each obesity medication. Studies have found that educating health care professionals on obesity care, including obesity medications, leads to increased self-efficacy in discussing obesity medications (238,239).

Prior to prescribing an obesity medication, health care professionals should complete a comprehensive evaluation that includes eliciting a history relevant to obesity, performing a physical examination, and obtaining laboratory testing to evaluate for obesity-related diseases and complications that may inform selection of obesity medication. Table 2.6 provides a brief overview of select history and physical exam elements that should be obtained. A future section of the "Standards of Care for Overweight and Obesity" will provide recommendations and additional details regarding the diagnosis, evaluation, and staging of obesity. A comprehensive physical examination should be performed to evaluate for causes of obesity (37). Height and weight should be measured, and BMI should be calculated to categorize the class of obesity. Waist circumference should be measured with the proper technique, and waist-to-height ratio should be calculated ($\geq$0.5 indicates central adiposity with increased risk of T2D and cardiovascular disease) (240,241). Blood pressure should be measured with an appropriately sized cuff to minimize measurement error; importantly, blood pressure values are used to inform obesity medication selection (e.g., elevated blood pressure is a contraindication to naltrexone-bupropion and phentermine).

Health care professionals should document whether an individual has a history of the following obesity-related diseases and complications that may inform obesity medication selection: prediabetes, T2D, hypertension, ASCVD, HFpEF, MASH, OSA, or osteoarthritis. If the individual has not been evaluated for these conditions, the health care professional should obtain a history and complete a physical examination pertinent to the condition and obtain additional testing, as appropriate, to establish a diagnosis (Table 2.6). Clinical practices should be prepared to conduct comprehensive initial evaluations and to continue monitoring identified obesity-related diseases and complications over time.

As obesity medications must be used in combination with lifestyle modification, clinical practices should determine their approach to delivering this care, either as a service provided within the practice or in collaboration with health care professionals or services outside the practice. Lifestyle interventions can be delivered within the primary care setting. A systematic review (56 RCTs) showed that primary care–based interventions for adults with obesity were effective in reducing weight and waist circumference (242); the average intervention duration

TABLE 2.6 Select components of a medical evaluation suggested prior to prescribing obesity medications*

History elements	Physical examination elements	Diagnostic testing elements
Weight history • Weight gain pattern and body weight trajectory • Highest and lowest body weight as an adult • Characteristics at the onset of overweight (e.g., age, life events, contributing factors) • Past or current use of weight-promoting medications • Past and current treatments and responses, including lifestyle, medication, procedures, and surgery • Past and current disordered eating • Personal goals and readiness to change Lifestyle behaviors • Eating patterns • Physical activity • Stress and coping • Sleep • Personal and cultural preferences for nutrition and physical activity Past medical history of obesity-related diseases and complications† • Prediabetes • Type 2 diabetes • Hypertension • Atherosclerotic cardiovascular disease • Heart failure with preserved ejection fraction • Metabolic dysfunction–associated steatohepatitis or metabolic dysfunction–associated steatotic liver disease • Obstructive sleep apnea • Knee osteoarthritis • Others People of childbearing potential • Current contraception strategy • Upcoming plans for pregnancy	Anthropometrics • Weight and height (measured) • Calculate BMI • Waist circumference (measured), as appropriate‡ • Calculate waist-to-height ratio, as appropriate‡ Vital signs • Blood pressure (measured) • Heart rate (measured) Physical examination • Cardiac exam • Pulmonary exam	Laboratory testing • A1C • Electrolytes including Cr and eGFR • AST, ALT, and platelet count to calculate FIB-4 • TSH • Lipid panel • Urine pregnancy test Other testing, as clinically appropriate • Echocardiogram • Vibration-controlled transient elastography • Sleep study • Knee X-ray

ALT, alanine aminotransferase; AST, aspartate aminotransferase; Cr, creatinine; eGFR, estimated glomerular filtration rate; FIB-4, fibrosis-4 score; TSH, thyroid-stimulating hormone. *Health care professionals should consider the listed elements as part of a medical evaluation prior to prescribing an obesity medication; however, this list should not be interpreted as required or as the only elements that should be assessed (e.g., family history, social history). †The specific diseases and complications listed identify conditions that may influence selection of obesity medication. If individuals do not have a history of any of these conditions, health care professionals should assess whether an individual has symptoms suggestive of one of these conditions that would warrant further diagnostic testing. ‡Measurement of waist circumference and calculation of waist-to-height ratio may be warranted to identify individuals at elevated risk of morbidity and mortality (257–259).

was approximately 12 months. Another systematic review (12 RCTs) in adults with obesity receiving behavioral treatment through primary care found that interventions prescribing reduced energy intake (e.g., ≥500 kcal/day deficit) and increased physical activity with traditional behavioral therapy were associated with greater weight reduction than interventions without these three specific components (243). In addition, more treatment sessions delivered by trained interventionists (in-person or remote) were associated with greater weight reduction. As appropriate, clinical practices may consider referring individuals with obesity to IBT or structured lifestyle programs in their community. The effectiveness of combining obesity medication with a structured lifestyle program has also been demonstrated with an employer-based weight management program (165) and within the Veterans Health Administration's MOVE! weight management program (166). Clinical practices can also consider delivering IBT within the practice. An RCT evaluated liraglutide 3.0 mg with IBT versus IBT with placebo in adults with obesity in a primary care setting (23); the delivery of IBT within the primary care setting was feasible, and the combination of liraglutide and IBT resulted in significantly greater weight reduction than IBT alone.

Following up with individuals started on obesity medications is recommended at least monthly for the first 3 months of treatment to support medication-taking behavior by assessing efficacy, managing adverse effects, and monitoring health status. Adverse effects from obesity medications are more likely to occur at initiation and with dose escalations (60,61), and frequent contact with the health care team may help support individuals

experiencing these effects. Table 2.1 includes strategies on how to manage common adverse effects for each obesity medication; health care professionals should also develop a differential diagnosis for significant adverse effects and exclude other potential causes or contributors to the symptoms. Unless clinical circumstances (such as poor medication tolerability) or other considerations (such as financial expense) suggest otherwise, individuals who achieve sufficient early weight reduction with an obesity medication (typically defined as ≥5% weight reduction after 3 months) should continue the medication long term. Modeling from clinical trials shows that early responders have improved long-term outcomes (244,245). When early weight reduction results are modest, the benefits of ongoing treatment need to be examined in the context of dose-escalation progress, treatment tolerance, improvements in obesity-related diseases and complications, the availability of other treatment options, and overall treatment burden. During this initial period, follow-up can be delivered via telehealth with interprofessional team members to facilitate timely and effective care. An RCT evaluating the comparative effectiveness of a behavioral weight-reduction intervention found that both in-person and remotely delivered interventions led to significant weight reduction compared with control and that the weight change did not differ significantly between the two intervention groups (246). Real-world evidence also supports the use of telehealth care delivered by clinical practices, which achieves similar outcomes to in-person visits (247–249).

After this initial 3-month period, regular follow-up care with individuals on obesity medications is needed to continue monitoring the efficacy and safety of the treatment plan. Real-world data from an academic obesity medicine clinic found that a greater number of follow-up visits was associated with greater weight reduction (150), which underscores the importance of regular interaction between individuals with obesity and health care professionals. Health care professionals should arrange for follow-up at least every 3 months for the remainder of the first year of treatment and plan for follow-up at least every 6 months for long-term management. Ongoing monitoring of the achievement and maintenance of treatment and weight-reduction goals is recommended. For individuals not reaching or maintaining treatment goals, treatment inertia should be avoided by reevaluating ongoing obesity therapies and intensifying treatment with additional approaches. Shared decision-making should be used to determine the best long-term obesity treatment approach. See the section above on Long-term Management of Obesity Medications for additional information.

Health care teams should be knowledgeable about health insurance formularies and obesity medication coverage requirements, as well as eligibility for medication assistance programs, copayment reduction cards, and direct-to-consumer cash pay options. Clinical practices should anticipate that most prescriptions for obesity medications will require prior authorization. U.S. health care professionals have reported that prior authorization alters their prescribing behaviors generally (250). A systematic review (46 studies) found that prior authorization and step therapy requirements were associated with lower medication use, which negatively affected medication-taking behaviors and clinical outcomes (251). Therefore, clinical practices should consider allocating resources to manage prior authorizations for obesity medications. Pharmacists or pharmacy technicians may also be able to assist with this process. Given that insurance coverage and costs may influence treatment decisions, payors should cover evidence-based obesity medications, particularly for people with obesity-related diseases and complications, to improve access and outcomes. Real-world research found that individuals who combined obesity medication with an intensive lifestyle program were significantly more likely to achieve clinically significant weight reductions and improve cardiometabolic markers (e.g., blood pressure and A1C) at 6, 12, and 24 months as compared with an intensive lifestyle program alone (166). Notably, the individuals prescribed obesity medication with the program also had fewer inpatient hospitalizations and emergency department visits than those who completed the lifestyle program alone, which resulted in lower medical costs.

Conclusions

Stakeholders, including individuals with obesity, health care professionals, policy makers, insurers, and employers, increasingly recognize the need for safe and effective pharmacotherapy to treat obesity. The ADA's Obesity Association encourages health care professionals to adopt and implement the present recommendations on obesity medications as part of a comprehensive obesity treatment plan for adults. Evidence supports the use of obesity medications in combination with lifestyle interventions to achieve long-term health and weight reduction goals. Obesity medications should be discussed with all individuals with obesity, and treatment plans for individuals with obesity who have or are at high risk of obesity-related diseases and complications should prioritize use of obesity medications with demonstrated benefit in improving the individuals' obesity-related diseases. Given the various pharmacologic approaches now in development, additional obesity medications are likely to come to market in coming years that may further expand treatment options.

Appendix

American Diabetes Association Professional Practice Committee for Obesity. Committee members include Kimberly A. Gudzune,||*** Caroline M. Apovian, Vanita R. Aroda, Louis J. Aronne,*** Kirthikaa Balapattabi,** Allison K.

Bennett,** Sathyavathi ChallaSivaKanaka,** Nuha A. ElSayed, Angela Fitch, Stephanie L. Fitzpatrick, W. Timothy Garvey, Samar Hafida,** Scott Kahan, Kamlesh Khunti, Robert F. Kushner, Joshua J. Neumiller, John W. Ostrominski,* Elizabeth J. Pekas,** Leigh Perreault, Alpana P. Shukla,* Fatima Cody Stanford, and Raveendhara R. Bannuru. ||PPC Chair. *Additional experts who are not part of PPC. **Scientific team. ***Subcommittee lead.

ACKNOWLEDGMENTS

The ADA thanks Michael Bonar and Charlie Franklin for figure design.

FUNDING

The Standards of Care guideline is funded by ADA general revenue. No other entity, including industry, provides financial support for the guideline. Committee members received no remuneration for their participation in development of this guideline.

DUALITY OF INTEREST

All authors have completed the required disclosures in accordance with the guidelines of the ADA and its subdivision, The Obesity Association. Competing interests, where applicable, have been transparently disclosed and assessed by the ADA's duality of interest review panel. Authors with relevant conflicts of interest were excluded from discussions or decisions related to specific recommendations to maintain the integrity of the guideline development process. Full disclosure statements for all contributors are available upon request.

AUTHOR CONTRIBUTIONS

The development of these clinical guidelines involved contributions from all listed individuals of the American Diabetes Association Professional Practice Committee for Obesity (K.A.G., C.M.A., V.R.A., L.J.A., K.B., A.K.B., S.C., N.A.E., A.F., S.L.F., W.T.G., S.H., S.K., K.K., R.F.K., J.J.N., J.W.O., E.J.P., L.P., A.P.S., F.C.S., and R.R.B.) in the planning, conduct, and reporting of the work. All subcommittee members contributed to conception and design, conduct, acquisition of data or analysis, and interpretation of data and contributed to planning and drafting of the manuscript. All committee members contributed to conception, planning, and data interpretation and reviewed the manuscript and provided critical feedback. The American Diabetes Association Professional Practice Committee for Obesity collaboratively reviewed and approved the final guidelines. R.R.B. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All contributors have provided their consent for inclusion in this statement.

REFERENCES

1. LeBlanc ES, Patnode CD, Webber EM, Redmond N, Rushkin M, O'Connor EA. Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2018;320:1172–1191

2. Shi Q, Wang Y, Hao Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet 2024;403:e21–e31

3. Qin W, Yang J, Ni Y, et al. Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: an updated systematic review and meta-analysis including the latest SURMOUNT-2 trial. Endocrine 2024;86:70–84

4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221–2232

5. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311–322

6. Malhotra A, Grunstein RR, Fietze I, et al.; SURMOUNT-OSA Investigators. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med 2024;391:1193–1205

7. Sanyal AJ, Newsome PN, Kliers I, et al.; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med 2025;392:2089–2099

8. Korner J, Aronne LJ. The emerging science of body weight regulation and its impact on obesity treatment. J Clin Invest 2003;111:565–570

9. Lowe MR. Self-regulation of energy intake in the prevention and treatment of obesity: is it feasible? Obes Res 2003;11(Suppl.):44s–59s

10. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011;365:1597–1604

11. Fothergill E, Guo J, Howard L, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity (Silver Spring) 2016;24:1612–1619

12. Moiz A, Filion KB, Toutounchi H, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: a systematic review of randomized controlled trials. Ann Intern Med 2025;178:199–217

13. Roh E, Choi KM. Hormonal gut-brain signaling for the treatment of obesity. Int J Mol Sci 2023;24:3384

14. Bray GA, Purnell JQ. An historical review of steps and missteps in the discovery of anti-obesity drugs. In: *Endotext*. Feingold KR, Ahmed SF, Anawalt B, et al., Eds. South Dartmouth, MA, 2000. Accessed 9 July 2025. Available from https://www.ncbi.nlm.nih.gov/pubmed/35834619

15. Bannuru RR; ADA Professional Practice Committee (PPC). Introduction and methodology: Standards of Care in Overweight and Obesity—2025. BMJ Open Diabetes Res Care 2025;13:e004928

16. Mitropoulou P, Grüner-Hegge N, Reinhold J, Papadopoulou C. Shared decision making in cardiology: a systematic review and meta-analysis. Heart 2022;109:34–39

17. Elias S, Chen Y, Liu X, et al. Shared decision-making in cardiovascular risk factor management: a systematic review and meta-analysis. JAMA Netw Open 2024;7:e243779

18. Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205–216

19. Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc 2007;107:1755–1767

20. Recchia F, Leung CK, Yu AP, et al. Dose-response effects of exercise and caloric restriction on visceral adiposity in overweight and obese adults: a systematic review and meta-

analysis of randomised controlled trials. Br J Sports Med 2023;57:1035–1041

21. Lundgren JR, Janus C, Jensen SBK, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med 2021;384:1719–1730

22. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011;19:110–120

23. Wadden TA, Walsh OA, Berkowitz RI, et al. Intensive behavioral therapy for obesity combined with liraglutide 3.0 mg: a randomized controlled trial. Obesity (Silver Spring) 2019;27:75–86

24. Wadden TA, Bailey TS, Billings LK, et al.; STEP 3 Investigators. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 2021;325:1403–1413

25. Wadden TA, Chao AM, Machineni S, et al. Author Correction: tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med 2024;30:1784–2918

26. Tronieri JS, Fabricatore AN, Wadden TA, et al. Effects of dietary self-monitoring, physical activity, liraglutide 3.0 mg, and placebo on weight loss in the SCALE IBT trial. Obes Facts 2020;13:572–583

27. Tronieri JS, Wadden TA, Walsh O, et al. Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial. Int J Obes (Lond) 2020;44:353–361

28. Chao AM, Wadden TA, Walsh OA, et al. Effects of liraglutide and behavioral weight loss on food cravings, eating behaviors, and eating disorder psychopathology. Obesity (Silver Spring) 2019;27:2005–2010

29. Hales CM, Gu Q, Ogden CL, Yanovski SZ. Use of prescription medications associated with weight gain among US adults, 1999-2018: a nationally representative survey. Obesity (Silver Spring) 2022;30:229–239

30. Almazan E, Schwartz JL, Gudzune KA. Use of medications associated with weight change among participants in the All of Us research programme. Clin Obes 2023;13:e12609

31. Galindo RJ, Uppal TS, McCoy RG, Umpierrez GE, Ali MK. Use and continuity of weight-modifying medications among adults with diabetes and overweight/obesity: US population study. Obesity (Silver Spring) 2023;31:2924–2935

32. Domecq JP, Prutsky G, Leppin A, et al. Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab 2015;100:363–370

33. Stanford FC, Cena H, Biino G, et al. The association between weight-promoting medication use and weight gain in postmenopausal women: findings from the Women's Health Initiative. Menopause 2020;27:1117–1125

34. Desalermos A, Russell B, Leggett C, et al. Effect of obesogenic medications on weight-loss outcomes in a behavioral weight-management program. Obesity (Silver Spring) 2019;27:716–723

35. Moon RC, Almuwaqqat Z. Effect of obesogenic medication on weight- and fitness-change outcomes: evidence from the Look AHEAD study. Obesity (Silver Spring) 2020;28:2003–2009

36. Sharma AM, Kushner RF. A proposed clinical staging system for obesity. Int J Obes (Lond) 2009;33:289–295

37. Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol 2025;13:221–262

38. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352:167–172

39. Greenway FL, Fujioka K, Plodkowski RA, et al.; COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376:595–605

40. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341–1352

41. Pi-Sunyer X, Astrup A, Fujioka K, et al.; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11–22

42. Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989–1002

43. Douketis JD, Macie C, Thabane L, Williamson DF. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond) 2005;29:1153–1167

44. Pan X-H, Tan B, Chin YH, et al. Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis. Obesity (Silver Spring) 2024;32:840–856

45. Wing RR, Lang W, Wadden TA, et al.; Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011;34:1481–1486

46. Loomba R, Hartman ML, Lawitz EJ, et al.; SYNERGY-NASH Investigators. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med 2024;391:299–310

47. Kosiborod MN, Abildstrøm SZ, Borlaug BarryA, et al.; STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389:1069–1084

48. Packer Milton, Zile MichaelR, Kramer ChristopherM, et al.; SUMMIT Trial Study Group. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 2025;392:427–437

49. Bliddal Henning, Bays Harold, Czernichow Sébastien, et al.; STEP 9 Study Group. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med 2024;391:1573–1583

50. Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring) 2013;21:2163–2171

51. McGowan B, Ciudin A, Baker JL, et al. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nat Med 2025;31:3317–3329

52. Haddock CK, Poston WSC, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four

decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002;26:262–273

53. Tronieri JS, Ghanbari E, Chevinsky J, et al. Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial. Nat Med 2025;31:1653–1660

54. Hollander P, Bays HE, Rosenstock J, et al. Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: a randomized clinical trial. Diabetes Care 2017;40:632–639

55. Lewis KH, Fischer H, Ard J, et al. Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort. Obesity (Silver Spring) 2019;27:591–602

56. Bays HE, Lazarus E, Primack C, Fitch A. Obesity pillars roundtable: phentermine - past, present, and future. Obes Pillars 2022;3:100024

57. Grunvald E, Shah R, Hernaez R, et al.; AGA Clinical Guidelines Committee. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology 2022;163:1198–1225

58. Berning P, Adhikari R, Schroer AE, et al. Longitudinal analysis of obesity drug use and public awareness. JAMA Netw Open 2025;8:e2457232

59. Rodriguez PJ, Zhang V, Gratzl S, et al. Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Netw Open 2025;8:e2457349

60. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab 2022; 24:94–105

61. Rubino DM, Pedersen SD, Connery L, et al. Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. Diabetes Obes Metab 2025;27:1826–1835

62. Aronne LJ, Horn DB, le Roux CW, et al.; SURMOUNT-5 Trial Investigators. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 2025;393:26–36

63. Almandoz JP, Wadden TA, Tewksbury C, et al. Nutritional considerations with antiobesity medications. Obesity (Silver Spring) 2024;32:1613–1631

64. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr 2025;122:344–367

65. Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006;29:2102–2107

66. Garvey WT, Ryan DH, Henry R, et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care 2014;37:912–921

67. Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 2012;367:695–704

68. Booth H, Khan O, Prevost T, et al. Incidence of type 2 diabetes after bariatric surgery: population-based matched cohort study. Lancet Diabetes Endocrinol 2014;2:963–968

69. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155–161

70. Le Roux CW, Astrup A, Fujioka K, et al.; SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 2017;389:1399–1409

71. McGowan BM, Bruun JM, Capehorn M, et al.; STEP 10 Study Group. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol 2024;12:631–642

72. Kahn SE, Deanfield JE, Jeppesen OK, et al.; SELECT Trial Investigators. Effect of semaglutide on regression and progression of glycemia in people with overweight or obesity but without diabetes in the SELECT trial. Diabetes Care 2024;47:1350–1359

73. Jastreboff AM, le Roux CW, Stefanski A, et al.; SURMOUNT-1 Investigators. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med 2025;392:958–971

74. Nauck MA, Quast DR, Wefers J, Pfeiffer AFH. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update. Diabetes Obes Metab 2021;23(Suppl. 3):5–29

75. Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (Lausanne) 2024;15:1431292

76. American Diabetes Association Professional Practice Committee for Diabetes. 8. Obesity and weight management for the prevention and treatment of diabetes: Standards of Care in Diabetes—2026. Diabetes Care 2026;49:S166–S182

77. Bays HE. Why does type 2 diabetes mellitus impair weight reduction in patients with obesity? A review. Obes Pillars 2023;7:100076

78. Garvey WT, Frias JP, Jastreboff AM, et al.; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402:613–626

79. Davies M, Færch L, Jeppesen OK, et al.; STEP 2 Study Group. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021;397:971–984

80. Davies MJ, Bergenstal R, Bode B, et al.; NN8022-1922 Study Group. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 2015;314:687–699

81. Garvey WT, Ryan DH, Bohannon NJ, et al. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care 2014;37:3309–3316

82. Hollander P, Gupta AK, Plodkowski R, et al.; COR-Diabetes Study Group. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and

glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013;36:4022–4029

83. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998;21:1288–1294

84. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 2021;398:143–155

85. Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol 2017;5:251–260

86. Garber A, Henry R, Ratner R, et al.; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473–481

87. Garrison RJ, Kannel WB, Stokes J, Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987;16:235–251

88. Forman JP, Stampfer MJ, Curhan GC. Diet and lifestyle risk factors associated with incident hypertension in women. JAMA 2009;302:401–411

89. Siebenhofer A, Winterholer S, Jeitler K, et al. Long-term effects of weight-reducing drugs in people with hypertension. Cochrane Database Syst Rev 2021;1:CD007654

90. Ala M, Moheb Aleaba M. The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression. J Endocrinol Invest 2025;48:283–294

91. Zhao X, Huang K, Zheng M, Duan J. Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials. BMC Endocr Disord 2019;19:4

92. Krumholz HM, de Lemos JA, Sattar N, et al. Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial. Heart 2024;110:1165–1171

93. Kennedy C, Hayes P, Cicero AFG, et al. Semaglutide and blood pressure: an individual patient data meta-analysis. Eur Heart J 2024;45:4124–4134

94. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95:297–308

95. de Lemos JA, Linetzky B, le Roux CW, et al. Tirzepatide reduces 24-hour ambulatory blood pressure in adults with body mass index ≥27 kg/m2: SURMOUNT-1 ambulatory blood pressure monitoring substudy. Hypertension 2024;81:e41–e43

96. Ansari M, Javadi H, Pourbehi M, et al. The association of rate pressure product (RPP) and myocardial perfusion imaging (MPI) findings: a preliminary study. Perfusion 2012;27:207–213

97. White WB. Heart rate and the rate-pressure product as determinants of cardiovascular risk in patients with hypertension. Am J Hypertens 1999;12:50s–55s

98. Whitman M, Jenkins C, Sabapathy S, Adams L. Comparison of heart rate blood pressure product versus age-predicted maximum heart rate as predictors of cardiovascular events during exercise stress echocardiography. Am J Cardiol 2019;124:528–533

99. Powell-Wiley TM, Poirier P, Burke LE, et al.; American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Stroke Council. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2021;143:e984–e1010

100. Reis JP, Allen N, Gunderson EP, et al. Excess body mass index- and waist circumference-years and incident cardiovascular disease: the CARDIA study. Obesity (Silver Spring) 2015;23:879–885

101. Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369:145–154

102. Gregg EW, Jakicic JM, Blackburn G, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2016;4:913–921

103. Cleto AS, Schirlo JM, Beltrame M, et al. Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis. Int J Obes (Lond) 2025;49:21–30

104. Ryan DH, Lingvay I, Deanfield J, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med 2024;30:2049–2057

105. Colhoun HM, Lingvay I, Brown PM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med 2024;30:2058–2066

106. Davies MJ, Aronne LJ, Caterson ID, Thomsen AB, Jacobsen PB, Marso SP; Satiety and Clinical Adiposity – Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: a post hoc analysis from SCALE randomized controlled trials. Diabetes Obes Metab 2018;20:734–739

107. Aronne LJ, Sattar N, Horn DB, et al.; SURMOUNT-4 Investigators. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331:38–48

108. Hankosky ER, Wang H, Neff LM, et al. Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis. Diabetes Obes Metab 2024;26:319–328

109. Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med 2022;28:591–598

110. Nissen SE, Wolski KE, Prcela L, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA 2016;315:990–1004

111. Savji N, Meijers WC, Bartz TM, et al. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF. JACC Heart Fail 2018;6:701–709

112. Qin H, Tromp J, Ter Maaten JM, et al. Clinical and proteomic risk profiles of new-onset heart failure in men and women. JACC Heart Fail 2025;13:435–449

113. Tsujimoto T, Kajio H. Abdominal obesity is associated with an increased risk of all-cause mortality in patients with HFpEF. J Am Coll Cardiol 2017;70:2739–2749

114. Peikert A, Vaduganathan M, Claggett BL, et al. Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial. Eur Heart J 2025;46:2372–2390

115. van Essen BJ, Emmens JE, Tromp J, et al. Sex-specific risk factors for new-onset heart failure: the PREVEND study at 25 years. Eur Heart J 2025;46:1528–1536

116. Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 2017;136:6–19

117. Lee VYJ, Houston L, Perkovic A, et al. The effect of weight loss through lifestyle interventions in patients with heart failure with preserved ejection fraction-a systematic review and meta-analysis of randomised controlled trials. Heart Lung Circ 2024;33:197–208

118. Butler J, Shah SJ, Petrie MC, et al.; STEP-HFpEF Trial Committees and Investigators. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet 2024;403:1635–1648

119. Shah SJ, Sharma K, Borlaug BA, et al. Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials. Eur Heart J 2024;45:3254–3269

120. Solomon SD, Ostrominski JW, Wang X, et al.; STEP-HFpEF Trial Committees and Investigators. Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure. J Am Coll Cardiol 2024;84:1587–1602

121. Kosiborod MN, Deanfield J, Pratley R, et al.; SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM Trial Committees and Investigators. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet 2024;404:949–961

122. Kramer CM, Borlaug BA, Zile MR, et al.; SUMMIT Trial Study Group. Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy. J Am Coll Cardiol 2025;85:699–706

123. Zile MR, Borlaug BA, Kramer CM, et al.; SUMMIT Trial Study Group. Effects of tirzepatide on the clinical trajectory of patients with heart failure, preserved ejection fraction, and obesity. Circulation 2025;151:656–668

124. Cusi K, Abdelmalek MF, Apovian CM, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. a consensus report of the American Diabetes Association. Diabetes Care 2025;48:1057–1082

125. Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology 2020;158:1611–1625.e1612

126. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 2017;65:1557–1565

127. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015;149:367–378 e365; quiz e314-e365

128. Newsome PN, Buchholtz K, Cusi K, et al.; NN9931-4296 Investigators. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021;384:1113–1124

129. Loomba R, Abdelmalek MF, Armstrong MJ, et al.; NN9931-4492 investigators. Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol 2023;8:511–522

130. Bandyopadhyay S, Das S, Samajdar SS, Joshi SR. Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis. Diabetes Metab Syndr 2023;17:102849

131. Armstrong MJ, Gaunt P, Aithal GP, et al.; LEAN trial team. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016;387:679–690

132. Khoo J, Hsiang JC, Taneja R, et al. Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease. Liver Int 2019;39:941–949

133. Khoo J, Hsiang J, Taneja R, Law NM, Ang TL. Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: a pilot randomized trial. Diabetes Obes Metab 2017;19:1814–1817

134. Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA 2000;284:3015–3021

135. Holmstrom L, Junttila J, Chugh SS. Sudden death in obesity: mechanisms and management. J Am Coll Cardiol 2024;84:2308–2324

136. Adabag S, Huxley RR, Lopez FL, et al. Obesity related risk of sudden cardiac death in the atherosclerosis risk in communities study. Heart 2015;101:215–221

137. Foster GD, Borradaile KE, Sanders MH, et al.; Sleep AHEAD Research Group of Look AHEAD Research Group. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med 2009;169:1619–1626

138. Kuna ST, Reboussin DM, Strotmeyer ES, et al.; Sleep AHEAD Research Subgroup of the Look AHEAD Research Group. Effects of weight loss on obstructive sleep apnea severity. ten-year results of the Sleep AHEAD study. Am J Respir Crit Care Med 2021;203:221–229

139. Winslow DH, Bowden CH, DiDonato KP, McCullough PA. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults. Sleep 2012;35:1529–1539

140. Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond) 2016;40:1310–1319

141. McEvoy RD, Antic NA, Heeley E, et al.; SAVE Investigators and Coordinators. CPAP for prevention of cardiovascular

events in obstructive sleep apnea. N Engl J Med 2016;375:919–931

142. Loffler KA, Heeley E, Freed R, et al.; SAVE Substudy Investigators. Continuous positive airway pressure treatment, glycemia, and diabetes risk in obstructive sleep apnea and comorbid cardiovascular disease. Diabetes Care 2020;43:1859–1867

143. Coggon D, Reading I, Croft P, McLaren M, Barrett D, Cooper C. Knee osteoarthritis and obesity. Int J Obes Relat Metab Disord 2001;25:622–627

144. Blagojevic M, Jinks C, Jeffery A, Jordan KP. Risk factors for onset of osteoarthritis of the knee in older adults: a systematic review and meta-analysis. Osteoarthritis Cartilage 2010;18:24–33

145. Riddle DL, Stratford PW. Body weight changes and corresponding changes in pain and function in persons with symptomatic knee osteoarthritis: a cohort study. Arthritis Care Res (Hoboken) 2013;65:15–22

146. Bliddal H, Leeds AR, Christensen R. Osteoarthritis, obesity and weight loss: evidence, hypotheses and horizons - a scoping review. Obes Rev 2014;15:578–586

147. Bartholdy C, Overgaard A, Gudbergsen H, Bliddal H, Kristensen LE, Henriksen M. Changes in physical activity during a one-year weight loss trial with liraglutide vs placebo in participants with knee osteoarthritis: secondary analyses of a randomised controlled trial. Osteoarthr Cartil Open 2022;4:100255

148. Baser O, Rodchenko K, Vivier E, Baser I, Lu Y, Mohamed M. The impact of approved anti-obesity medications on osteoarthritis. Expert Opin Pharmacother 2024;25:1565–1573

149. Hankosky ER, Chinthammit C, Meeks A, et al. Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: results from the Optum Market Clarity database. Diabetes Obes Metab 2025;27:2810–2821

150. Weintraub MA, D'Angelo D, Tchang BG, et al. Five-year weight loss maintenance with obesity pharmacotherapy. J Clin Endocrinol Metab 2023;108:e832–e841

151. Wilding JPH, Batterham RL, Davies M, et al.; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022;24:1553–1564

152. Rubino D, Abrahamsson N, Davies M, et al.; STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 2021;325:1414–1425

153. Garvey WT, Batterham RL, Bhatta M, et al.; STEP 5 Study Group. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022;28:2083–2091

154. Almohaileb FI, le Roux CW, Crotty M. Why do patients with obesity discontinue glucagon-like peptide 1 analogues? Diabetes Obes Metab 2025;27:5342–5345

155. Haggerty T, Dekeseredy P, Bailey J, Cowher A, Baus A, Davisson L. Navigating coverage: a qualitative study exploring the perceived impact of an insurance company policy to discontinue coverage of antiobesity medication. Obes Pillars 2024;11:100120

156. Tchang BG, Aras M, Wu A, Aronne LJ, Shukla AP. Long-term weight loss maintenance with obesity pharmacotherapy: a retrospective cohort study. Obes Sci Pract 2022;8:320–327

157. Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity (Silver Spring) 2014;22:5–13

158. Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA 2016;315:2424–2434

159. Ryder JR, Kaizer AM, Jenkins TM, Kelly AS, Inge TH, Shaibi GQ. Heterogeneity in response to treatment of adolescents with severe obesity: the need for precision obesity medicine. Obesity (Silver Spring) 2019;27:288–294

160. Overgaard RV, Lindberg S, Thielke D. Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: a model-based approach. Diabetes Obes Metab 2019;21:43–51

161. Urva S, Levine JA, Schneck K, Tang CC. Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide. Curr Med Res Opin 2024;40:567–574

162. Barakat S, Ramdeen S, Khaimova R. Safety and efficacy of switching patients with type 2 diabetes from glucagon-like peptide-1 receptor agonists to tirzepatide: a case series. Hosp Pharm 2024;59:614–619

163. Jabbour S, Paik JS, Aleppo G, Sharma P, Gomez Valderas E, Benneyworth BD. Switching to tirzepatide 5 mg from glucagon-like peptide-1 receptor agonists: clinical expectations in the first 12 weeks of treatment. Endocr Pract 2024;30:701–709

164. Billings LK, Winne L, Sharma P, Gomez-Valderas E, Chivukula KK, Kwan AYM. Comparison of dose escalation versus switching to tirzepatide among people with type 2 diabetes inadequately controlled on lower doses of dulaglutide: a randomized clinical trial. Ann Intern Med 2025;178:609–619

165. Pantalone KM, Smolarz BG, Ramasamy A, et al. Effectiveness of combining antiobesity medication with an employer-based weight management program for treatment of obesity: a randomized clinical trial. JAMA Netw Open 2021;4:e2116595

166. Garvey WT, Cheng M, Ramasamy A, et al. Clinical and cost benefits of anti-obesity medication for US veterans participating in the MOVE! weight management program. Popul Health Manag 2023;26:72–82

167. Wadden TA, Tronieri JS, Sugimoto D, et al. Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial. Obesity (Silver Spring) 2020;28:529–536

168. Wharton Sean, Yin Peter, Burrows Melonie, et al. Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial. Int J Obes (Lond) 2021;45:1687–1695

169. Tronieri JS, Wadden TA, Walsh OA, et al. Effects of liraglutide plus phentermine in adults with obesity following 1year of treatment by liraglutide alone: a randomized placebo-controlled pilot trial. Metabolism 2019;96:83–91

170. Schiavon CA, Cavalcanti AB, Oliveira JD, et al. Randomized trial of effect of bariatric surgery on blood pressure after 5 years. J Am Coll Cardiol 2024;83:637–648

171. Courcoulas AP, Patti ME, Hu B, et al. Long-term outcomes of medical management vs bariatric surgery in type 2 diabetes. JAMA 2024;331:654–664

172. Batsis JA, Sarr MG, Collazo-Clavell ML, et al. Cardiovascular risk after bariatric surgery for obesity. Am J Cardiol 2008;102:930–937

173. Miras AD, Pérez-Pevida B, Aldhwayan M, et al. Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2019;7:549–559

174. Murvelashvili N, Xie L, Schellinger JN, et al. Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence. Obesity (Silver Spring) 2023;31:1280–1289

175. Stanford FC, Alfaris N, Gomez G, et al. The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-center study. Surg Obes Relat Dis 2017;13:491–500

176. Cross V, Stanford J, Gómez-Martín M, Collins CE, Robertson S, Clarke ED. Do personalized nutrition interventions improve dietary intake and risk factors in adults with elevated cardiovascular disease risk factors? A systematic review and meta-analysis of randomized controlled trials. Nutr Rev 2025;83:e1709–e1721

177. Leavy JM, Clifton PM, Keogh JB. The role of choice in weight loss strategies: a systematic review and meta-analysis. Nutrients 2018;10:1136

178. Kushner RF. Barriers to providing nutrition counseling by physicians: a survey of primary care practitioners. Prev Med 1995;24:546–552

179. Henderson J, Ehlers AP, Lee JM, et al. Weight loss treatment and longitudinal weight change among primary care patients with obesity. JAMA Netw Open 2024;7:e2356183

180. Oshman L, Othman A, Furst W, et al. Primary care providers' perceived barriers to obesity treatment and opportunities for improvement: a mixed methods study. PLoS One 2023;18:e0284474

181. Morgan-Bathke M, Raynor HA, Baxter SD, et al. Medical nutrition therapy interventions provided by dietitians for adult overweight and obesity management: an academy of nutrition and dietetics evidence-based practice guideline. J Acad Nutr Diet 2023;123:520–545.e510

182. Morgan-Bathke M, Baxter SD, Halliday TM, et al. Weight management interventions provided by a dietitian for adults with overweight or obesity: an evidence analysis center systematic review and meta-analysis. J Acad Nutr Diet 2023;123:1621–1661.e1625

183. Mitchell LJ, Ball LE, Ross LJ, Barnes KA, Williams LT. Effectiveness of dietetic consultations in primary health care: a systematic review of randomized controlled trials. J Acad Nutr Diet 2017;117:1941–1962

184. Gigliotti L, Warshaw H, Evert A, et al. Incretin-based therapies and lifestyle interventions: the evolving role of registered dietitian nutritionists in obesity care. J Acad Nutr Diet 2025;125:408–421

185. Leidy HJ, Clifton PM, Astrup A, et al. The role of protein in weight loss and maintenance. Am J Clin Nutr 2015;101: 1320s–1329s

186. Panel on Dietary Reference Intakes for Electrolytes and Water; Standing Committee on the Scientific Evaluation of Dietary Reference Intakes; Food and Nutrition Board. *Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate*. Washington, DC, The National Academies Press, 2005. Accessed 16 October 2025. Available from https://nap.nationalacademies.org/read/10925/chapter/1

187. Agarwal S, Reider C, Brooks JR, Fulgoni VL, 3rd. Comparison of prevalence of inadequate nutrient intake based on body weight status of adults in the United States: an analysis of NHANES 2001-2008. J Am Coll Nutr 2015;34:126–134

188. Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab 2021;23:754–762

189. Heise T, DeVries JH, Urva S, et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care 2023;46:998–1004

190. Scott Butsch W, Sulo S, Chang AT, et al. Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: a retrospective observational study. Obes Pillars 2025;15:100186

191. Johnson B, Milstead M, Thomas O, et al. Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study. Front Nutr 2025;12:1566498

192. Marra MV, Bailey RL. Position of the Academy of Nutrition and Dietetics: micronutrient supplementation. J Acad Nutr Diet 2018;118:2162–2173

193. Blumberg JB, Frei BB, Fulgoni VL, Weaver CM, Zeisel SH. Impact of frequency of multi-vitamin/multi-mineral supplement intake on nutritional adequacy and nutrient deficiencies in U.S. adults. Nutrients 2017;9:849

194. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999;281:235–242

195. Heymsfield SB, Gonzalez MCC, Shen W, Redman L, Thomas D. Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule. Obes Rev 2014;15:310–321

196. Beavers KM, Cortes TM, Foy CM, et al. GLP1Ra-based therapies and DXA-acquired musculoskeletal health outcomes: a focused meta-analysis of placebo-controlled trials. Obesity (Silver Spring) 2025;33:225–237

197. Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis. Metabolism 2025;164:156113

198. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab 2025;27:2720–2729

199. Jobanputra R, Sargeant JA, Almaqhawi A, et al. The effects of weight-lowering pharmacotherapies on physical activity, function and fitness: a systematic review and meta-analysis of randomized controlled trials. Obes Rev 2023;24:e13553

200. Rubino D, Bjorner JB, Rathor N, et al. Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: patient-reported outcomes from the STEP 1-4 trials. Diabetes Obes Metab 2024;26:2945–2955

201. Donini LM, Busetto L, Bischoff SC, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Clin Nutr 2022;41:990–1000

202. Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle 2016;7:28–36

203. Kokura Y, Ueshima J, Saino Y, Maeda K. Enhanced protein intake on maintaining muscle mass, strength, and physical function in adults with overweight/obesity: a systematic review and meta-analysis. Clin Nutr ESPEN 2024;63:417–426

204. Tagawa R, Watanabe D, Ito K, et al. Synergistic effect of increased total protein intake and strength training on muscle strength: a dose-response meta-analysis of randomized controlled trials. Sports Med Open 2022;8:110

205. Lopez P, Taaffe DR, Galvão DA, et al. Resistance training effectiveness on body composition and body weight outcomes in individuals with overweight and obesity across the lifespan: a systematic review and meta-analysis. Obes Rev 2022;23: e13428

206. Jensen SBK, Blond MB, Sandsdal RM, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine 2024;69:102475

207. Jensen SBK, Sørensen V, Sandsdal RM, et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial. JAMA Netw Open 2024;7:e2416775

208. Muller DRP, Stenvers DJ, Malekzadeh A, Holleman F, Painter RC, Siegelaar SE. Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. Front Endocrinol (Lausanne) 2023;14:1215356

209. Margulis AV, Mitchell AA, Gilboa SM, et al. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol 2012;207:405.e1–e7

210. D'Adesky N, Ghosh S. Phentermine use during first and second trimesters associated with fetal stroke. Cureus 2019;11:e6170

211. Nelson HD, Cantor A, Jungbauer RM, et al. Effectiveness and harms of contraceptive counseling and provision interventions for women: a systematic review and meta-analysis. Ann Intern Med 2022;175:980–993

212. Lopez LM, Bernholc A, Chen M, et al. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev 2016;2016:CD008452

213. Hunter E, Avenell A, Maheshwari A, Stadler G, Best D. The effectiveness of weight-loss lifestyle interventions for improving fertility in women and men with overweight or obesity and infertility: a systematic review update of evidence from randomized controlled trials. Obes Rev 2021;22:e13325

214. Pavli P, Triantafyllidou O, Kapantais E, Vlahos NF, Valsamakis G. Infertility improvement after medical weight loss in women and men: a review of the literature. Int J Mol Sci 2024;25

215. Skelley JW, Swearengin K, York AL, Glover LH. The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception. J Am Pharm Assoc (2003) 2024;64:204–211.e4

216. Eli Lilly and Company. Zepbound (tirzepatide). Accessed 7 September 2025. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s013lbl.pdf

217. Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol 2015;55: 497–504

218. Jacobsen LV, Vouis J, Hindsberger C, Zdravkovic M. Treatment with liraglutide–a once-daily GLP-1 analog–does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug. J Clin Pharmacol 2011;51:1696–1703

219. Sarayani A, Winterstein A, Cristofoletti R, Vozmediano V, Schmidt S, Brown J. Real-world effect of a potential drug-drug interaction between topiramate and oral contraceptives on unintended pregnancy outcomes. Contraception 2023;120:109953

220. VIVUS. Qsymia (phentermine and topiramate extended-release). Accessed 7 September 2025. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022580s000lbl.pdf

221. Palovaara S, Pelkonen O, Uusitalo J, Lundgren S, Laine K. Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther 2003;74: 326–333

222. Hartmann D, Güzelhan C, Zuiderwijk PB, Odink J. Lack of interaction between orlistat and oral contraceptives. Eur J Clin Pharmacol 1996;50:421–424

223. Watson CJ, Whitledge JD, Siani AM, Burns MM. Pharmaceutical compounding: a history, regulatory overview, and systematic review of compounding errors. J Med Toxicol 2021;17:197–217

224. Hach M, Engelund DK, Mysling S, et al. Impact of manufacturing process and compounding on properties and quality of follow-on GLP-1 polypeptide drugs. Pharm Res 2024;41:1991–2014

225. Ashraf AR, Mackey TK, Schmidt J, et al. Safety and risk assessment of no-prescription online semaglutide purchases. JAMA Netw Open 2024;7:e2428280

226. McCall KL, Mastro Dwyer KA, Casey RT, et al. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. Expert Opin Drug Saf 2025:1–8

227. Gaw CE, Hays HL, Kemp CA, et al. Glucagon-like peptide-1 receptor agonist cases reported to United States poison centers, 2017-2022. J Med Toxicol 2024;20:193–204

228. Chetty AK, Chillakanti M, Ramachandran R, Ross JS, Chen AS. Online advertising of compounded glucagon-like peptide-1 receptor agonists. JAMA Health Forum 2025;6: e245018

229. Neumiller JJ, Bajaj M, Bannuru RR, et al. Compounded GLP-1 and dual GIP/GLP-1 receptor agonists: a statement from the American Diabetes Association. Diabetes Care 2025;48:177–181

230. Gudzune KA, Brittan DR, Cadle AW, Reid TJ, Wickham EP, 3rd, Korner J. Duties, tasks, knowledge and skills of an obesity medicine physician: a practice analysis. Obes Pillars 2024;12:100147

231. Gudzune KA, Wickham EP, 3rd, Schmidt SL, Stanford FC. Physicians certified by the American Board of Obesity Medicine provide evidence-based care. Clin Obes 2021;11:e12407

232. Agarwal M, Nadolsky K. Attitudes, perceptions, and practices among endocrinologists managing obesity. Endocr Pract 2022;28:179–184

233. Rajagopal S, Wickham EP, 3rd, Reid TJ, Brittan DR, Korner J, Gudzune KA. Comparing clinical practice habits among obesity medicine physicians by patient, physician and clinic factors. Obes Pillars 2025;13:100157

234. Griauzde DH, Turner CD, Othman A, et al. A primary care-based weight navigation program. JAMA Netw Open 2024;7:e2412192

235. Mastrocola MR, Roque SS, Benning LV, Stanford FC. Obesity education in medical schools, residencies, and fellowships throughout the world: a systematic review. Int J Obes (Lond) 2020;44:269–279

236. Garvey WT, Mahle CD, Bell T, Kushner RF. Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP-1, GIP receptor agonists, and dual agonists. Obes Sci Pract 2024;10:e756

237. Campos A, Fantasia KL, Rizo I. Knowledge, attitudes, and practices in obesity among trained and in-training primary care providers in an urban safety-net hospital system. Obes Pillars 2025;15:100185

238. Iwamoto S, Saxon D, Tsai A, et al. Effects of education and experience on primary care providers' perspectives of obesity treatments during a pragmatic trial. Obesity (Silver Spring) 2018;26:1532–1538

239. Chae K, German J, Kendrick K, et al. An obesity medicine curriculum increases the obesity care self-efficacy of internal medicine residents in the primary care setting. Clin Obes 2024;14:e12656

240. Ashwell M, Gibson S. Waist to height ratio is a simple and effective obesity screening tool for cardiovascular risk factors: analysis of data from the British National Diet and Nutrition Survey of adults aged 19-64 years. Obes Facts 2009;2: 97–103

241. Dicker D, Karpati T, Promislow S, Reges O. Implications of the European Association for the Study of Obesity's new framework definition of obesity: prevalence and association with all-cause mortality. Ann Intern Med 2025;178:1065–1072

242. Marques ES, Interlenghi GS, Leite TH, et al. Primary care-based interventions for treatment of obesity: a systematic review. Public Health 2021;195:61–69

243. Wadden TA, Butryn ML, Hong PS, Tsai AG. Behavioral treatment of obesity in patients encountered in primary care settings: a systematic review. JAMA 2014;312:1779–1791

244. Fujioka K, O'Neil PM, Davies M, et al. Early Weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers. Obesity (Silver Spring) 2016;24:2278–2288

245. Fujioka K, Plodkowski R, O'Neil PM, Gilder K, Walsh B, Greenway FL. The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy. Int J Obes (Lond) 2016;40: 1369–1375

246. Appel LJ, Clark JM, Yeh HC, et al. Comparative effectiveness of weight-loss interventions in clinical practice. N Engl J Med 2011;365:1959–1968

247. Tchang BG, Morrison C, Kim JT, et al. Weight loss outcomes with telemedicine during COVID-19. Front Endocrinol (Lausanne) 2022;13:793290

248. Griebeler ML, Butsch WS, Rodriguez P, et al. The use of virtual visits for obesity pharmacotherapy in patients with overweight or obesity compared with in-person encounters. Obesity (Silver Spring) 2022;30:2194–2203

249. Latorre-Rodríguez AR, Shah RH, Munir S, Mittal SK. Adoption of telemedicine for obesity treatment during the COVID-19 pandemic achieved comparable outcomes to in-person visits. Obes Pillars 2024;12:100131

250. Salzbrenner SG, Lydiatt M, Helding B, et al. Influence of prior authorization requirements on provider clinical decision-making. Am J Manag Care 2023;29:331–337

251. Park Y, Raza S, George A, Agrawal R, Ko J. The effect of formulary restrictions on patient and payer outcomes: a systematic literature review. J Manag Care Spec Pharm 2017;23:893–901

252. Merative. Micromedex RED BOOK. Accessed 10 September 2025. Available from https://www-micromedexsolutions-com.ezproxymcp.flo.org/

253. Data.Medicaid.gov. NADAC (National Average Drug Acquisition Cost) 2025. Accessed 10 September 2025. Available from https://data.medicaid.gov/dataset/f38d0706-1239-442c-a3cc-40ef1b686ac0#overview

254. Nauck M, Frid A, Hermansen K, et al.; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84–90

255. Kosiborod MN, Petrie MC, Borlaug BA, et al.; STEP-HFpEF DM Trial Committees and Investigators. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med 2024;390:1394–1407

256. Gudbergsen H, Overgaard A, Henriksen M, et al. Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. Am J Clin Nutr 2021;113:314–323

257. Cerhan JR, Moore SC, Jacobs EJ, et al. A pooled analysis of waist circumference and mortality in 650,000 adults. Mayo Clin Proc 2014;89:335–345

258. Lee CM, Huxley RR, Wildman RP, Woodward M. Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. J Clin Epidemiol 2008;61:646–653

259. Browning LM, Hsieh SD, Ashwell M. A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 0.5 could be a suitable global boundary value. Nutr Res Rev 2010;23: 247–269

260. Apovian CM, Aronne L, Barenbaum SR. *Clinical Management of Obesity*. 3rd ed. The Obesity Society, 2025